


<OAI-PMH xmlns="http://www.openarchives.org/OAI/2.0/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
         xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd">
    <responseDate>2025-09-09T13:50:05Z</responseDate>
    <request verb="GetRecord" identifier="oai:pubmedcentral.nih.gov:12407849" metadataPrefix="pmc">https://pmc.ncbi.nlm.nih.gov/api/oai/v1/mh/</request>
    
    <GetRecord>
        <record>
    <header>
    <identifier>oai:pubmedcentral.nih.gov:12407849</identifier>
    <datestamp>2025-09-04</datestamp>
    
        
        <setSpec>mabs</setSpec>
        
    
        
        <setSpec>pmc-open</setSpec>
        
    
</header>
    <metadata>
        
        <article xmlns="https://jats.nlm.nih.gov/ns/archiving/1.4/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xsi:schemaLocation="https://jats.nlm.nih.gov/ns/archiving/1.4/ https://jats.nlm.nih.gov/archiving/1.4/xsd/JATS-archivearticle1-4.xsd" xml:lang="en" article-type="report" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">MAbs</journal-id><journal-id journal-id-type="iso-abbrev">MAbs</journal-id><journal-id journal-id-type="pmc-domain-id">934</journal-id><journal-id journal-id-type="pmc-domain">mabs</journal-id><journal-title-group><journal-title>mAbs</journal-title></journal-title-group><issn pub-type="ppub">1942-0862</issn><issn pub-type="epub">1942-0870</issn><publisher><publisher-name>Taylor &amp; Francis</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC12407849</article-id><article-id pub-id-type="pmcid-ver">PMC12407849.1</article-id><article-id pub-id-type="pmcaid">12407849</article-id><article-id pub-id-type="pmcaiid">12407849</article-id><article-id pub-id-type="pmid">40888053</article-id><article-id pub-id-type="doi">10.1080/19420862.2025.2551205</article-id><article-id pub-id-type="publisher-id">2551205</article-id><article-version-alternatives><article-version article-version-type="pmc-version">1</article-version><article-version vocab="JAV" vocab-identifier="http://www.niso.org/publications/rp/RP-8-2008.pdf" vocab-term="Version of Record" article-version-type="VoR">Version of Record</article-version></article-version-alternatives><article-categories><subj-group subj-group-type="article-type"><subject>Report</subject></subj-group><subj-group subj-group-type="heading"><subject>Report</subject></subj-group></article-categories><title-group><article-title>A bispecific antibody&#8211;drug conjugate targeting CD7 and CD33 shows anti-tumor activity and improved tumor selectivity in an aggressive subtype of acute myeloid leukemia</article-title><alt-title alt-title-type="left-running-head">H. B. S. GRIFFITHS ET AL.</alt-title><alt-title alt-title-type="right-running-head">MABS</alt-title></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-0443-8013</contrib-id><name name-style="western"><surname>Griffiths</surname><given-names initials="HBS">Hollie B. S.</given-names></name><xref rid="aff0001" ref-type="aff">
<sup>a</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Jones</surname><given-names initials="N">Nyle</given-names></name><xref rid="aff0001" ref-type="aff">
<sup>a</sup>
</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-0944-5423</contrib-id><name name-style="western"><surname>Vitale</surname><given-names initials="M">Mattia</given-names></name><xref rid="aff0001" ref-type="aff">
<sup>a</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Faulkner</surname><given-names initials="N">Nikhil</given-names></name><xref rid="aff0001" ref-type="aff">
<sup>a</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Masters</surname><given-names initials="EW">Edward W.</given-names></name><xref rid="aff0001" ref-type="aff">
<sup>a</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Nabi-Aldridge</surname><given-names initials="NLA">Naomi L. A.</given-names></name><xref rid="aff0001" ref-type="aff">
<sup>a</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Mistry</surname><given-names initials="M">Meera</given-names></name><xref rid="aff0001" ref-type="aff">
<sup>a</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Patterson</surname><given-names initials="C">Chloe</given-names></name><xref rid="aff0001" ref-type="aff">
<sup>a</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Blanco-Gomez</surname><given-names initials="A">Adrian</given-names></name><xref rid="aff0001" ref-type="aff">
<sup>a</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Griessinger</surname><given-names initials="E">Emmanuel</given-names></name><xref rid="aff0002" ref-type="aff">
<sup>b</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Schon</surname><given-names initials="O">Oliver</given-names></name><xref rid="aff0001" ref-type="aff">
<sup>a</sup>
</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0009-0009-7990-3563</contrib-id><name name-style="western"><surname>Daniels-Thorn</surname><given-names initials="TJ">Tiffany J.</given-names></name><xref rid="aff0001" ref-type="aff">
<sup>a</sup>
</xref><xref rid="an0001" ref-type="corresp"/></contrib><aff id="aff0001"><label>a</label><institution-wrap><institution>BiVictriX Therapeutics Ltd</institution></institution-wrap>, <city>Cheshire</city>, <country>UK</country></aff><aff id="aff0002"><label>b</label><institution-wrap><institution>Independent Researcher</institution></institution-wrap>, <city>Nice</city>, <country>France</country></aff></contrib-group><author-notes><corresp id="an0001">CONTACT Tiffany J. Daniels-Thorn <email xlink:href="mailto:Tiffany.Thorn@bivictrix.com">Tiffany.Thorn@bivictrix.com</email> BiVictriX Therapeutics Ltd, Alderley park, Alderley Edge, Cheshire SK10 4TG, UK</corresp></author-notes><pub-date date-type="pub" publication-format="electronic"><day>1</day><month>9</month><year>2025</year></pub-date><pub-date date-type="collection" publication-format="electronic"><year>2025</year></pub-date><volume>17</volume><issue>1</issue><issue-id pub-id-type="pmc-issue-id">477326</issue-id><elocation-id seq="82">2551205</elocation-id><pub-history><event event-type="pmc-release"><date><day>01</day><month>09</month><year>2025</year></date></event><event event-type="pmc-live"><date><day>04</day><month>09</month><year>2025</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2025-09-04 16:25:19.050"><day>04</day><month>09</month><year>2025</year></date></event><event event-type="tagger"><event-desc>Integra</event-desc><date><day>01</day><month>9</month><year>2025</year></date></event><event event-type="final"><event-desc>Integra</event-desc><date><day>01</day><month>9</month><year>2025</year></date></event><event event-type="received"><date><day>30</day><month>5</month><year>2025</year></date></event><event event-type="revised"><date><day>15</day><month>8</month><year>2025</year></date></event><event event-type="accepted"><date><day>18</day><month>8</month><year>2025</year></date></event></pub-history><permissions><copyright-statement>&#169; 2025 The Author(s). Published with license by Taylor &amp; Francis Group, LLC.</copyright-statement><copyright-year>2025</copyright-year><copyright-holder>The Author(s)</copyright-holder><license><ali:license_ref specific-use="textmining" content-type="ccbynclicense">https://creativecommons.org/licenses/by-nc/4.0/</ali:license_ref><license-p>This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (<ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nc/4.0/">http://creativecommons.org/licenses/by-nc/4.0/</ext-link>), which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. The terms on which this article has been published allow the posting of the Accepted Manuscript in a repository by the author(s) or with their consent.</license-p></license></permissions><self-uri content-type="pmc-pdf" xlink:href="KMAB_17_2551205.pdf"/><self-uri content-type="pdf" xlink:href="KMAB_17_2551205.pdf"/><abstract><title>ABSTRACT</title><p>Acute myeloid leukemia (AML) is a heterogeneous malignancy with poor clinical outcome. Aberrant expression of CD7 in AML patients is linked to shorter overall survival and lack of response to standard of care therapy. CD33/CD7 co-expression on leukemic blasts occurs in approximately one-third of AML patients and is known to be absent in normal myeloid cells. We propose that CD33<sup>+</sup>CD7<sup>+</sup> AML constitutes an aggressive subgroup characterized by poorer prognosis and enrichment in stem-cell associated gene signatures. To address the substantial unmet need in this patient cohort, we developed the antibody&#8211;drug conjugate BVX001, a CD33xCD7-targeted bispecific antibody-binding fragment linked to an auristatin payload. Importantly, BVX001 relies on simultaneous binding to CD33 and CD7 in <italic toggle="yes">cis</italic> through an &#8216;AND-gated&#8217; design, for optimal delivery of its cytotoxic payload. Consequently, BVX001 did not affect healthy myeloid progenitors or T cells at concentrations at which its monospecific counterparts showed toxicity. BVX001 induced significant tumor regression in AML cell line and patient-derived xenografts and increased overall survival. Finally, BVX001 showed significant blast ablation and reduced leukemic stem cell frequency in AML patient samples with both high and low target co-expression. Together, our findings support BVX001 as a new and promising approach for the treatment of this aggressive CD33<sup>+</sup>CD7<sup>+</sup> AML subtype, currently lacking targeted therapeutic options.</p></abstract><kwd-group kwd-group-type="author"><title>KEYWORDS</title><kwd>Acute myeloid leukemia</kwd><kwd>antibody drug conjugates</kwd><kwd>bispecific antibody drug conjugates</kwd></kwd-group><support-group><funding-group><award-group><funding-source><institution-wrap><institution>BiVictriX Therapeutics</institution></institution-wrap></funding-source></award-group><funding-statement>The work was funded by BiVictriX Therapeutics.</funding-statement></funding-group></support-group><counts><fig-count count="6"/><table-count count="2"/><ref-count count="50"/><page-count count="1"/><word-count count="7324"/></counts><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec sec-type="intro" disp-level="1" id="s0001"><title>Introduction</title><p>Acute myeloid leukemia (AML) is an aggressive hematological malignancy with poor survival.<sup><xref rid="cit0001" ref-type="bibr">1</xref>,<xref rid="cit0002" ref-type="bibr">2</xref></sup> Despite the increasing availability of targeted therapeutics, and the recent adoption of new approaches for elderly patients, many patients with AML ultimately succumb to their disease.<sup><xref rid="cit0003" ref-type="bibr">3</xref>,<xref rid="cit0004" ref-type="bibr">4</xref></sup> In view of the high incidence of relapsed and refractory disease, new therapeutic approaches are required. The high mutational and phenotypic heterogeneity of AML requires targeted approaches adapted to subgroups of patients.</p><p>Antibody-drug conjugates (ADCs) targeting a variety of antigens, including CD33, CD47, CD70, CD123, FLT3 and CLL-1,<sup><xref rid="cit0005" ref-type="bibr">5</xref></sup> are currently under evaluation for AML. ADCs consist of an antibody chemically linked to a cytotoxic drug, typically targeting a single surface antigen on malignant cells. Target-bound ADC is internalized via endosomes that fuse with lysosomes<sup><xref rid="cit0006" ref-type="bibr">6</xref></sup> where the toxic payload is released, inducing cell death. Mylotarg&#174;, Gemtuzumab-ozogamicin (GO), is an anti-CD33 IgG4 covalently linked to calicheamicin <underline>as the payload.</underline> GO was the first US Food and Drug Administration-approved ADC for the treatment of adult CD33<sup>+</sup> AML, however patients administered the drug <underline>often</underline> experience serious adverse effects.<sup><xref rid="cit0007" ref-type="bibr">7</xref></sup> Antibody therapeutics targeting CD123, including ADCs (e.g., IMGN632, AZD9829) and bispecific cell engagers (e.g., MGD024, IPH6101), are currently under development and have entered clinical trials.<sup><xref rid="cit0008" ref-type="bibr">8</xref></sup> However, these antibody-based therapeutics target single antigens where expression is not limited to the malignant cells and are, therefore, prone to on-target/off-tissue toxicities on antigen-positive healthy cells. Consequently, these therapies have a narrow therapeutic window, where adverse, potentially fatal side effects, are common.<sup><xref rid="cit0007" ref-type="bibr">7</xref></sup></p><p>It has been reported that CD7 expression on AML blasts is linked to poorer overall survival and failures following standard of care (SoC) treatment.<sup><xref rid="cit0009" ref-type="bibr">9&#8211;11</xref></sup> A recent study by Jen <italic toggle="yes">et al</italic>. found that patients with CD7<sup>+</sup> AML experienced a reduction in overall survival of ~7&#8201;months compared to CD7<sup>&#8722;</sup> patients.<sup><xref rid="cit0009" ref-type="bibr">9</xref></sup> Indeed, expression of CD7&#160;has been identified as a poor survival predictor in patients receiving treatment with Ven/Aza<sup><xref rid="cit0010" ref-type="bibr">10</xref></sup> and as a negative predictor of outcomes following allotransplant.<sup><xref rid="cit0011" ref-type="bibr">11</xref></sup></p><p>CD7 is a transmembrane glycoprotein that is expressed by healthy T and NK-cells and plays a costimulatory role in T-cell activation.<sup><xref rid="cit0009" ref-type="bibr">9</xref></sup> While healthy myeloid cells do not express CD7, aberrant expression of CD7 can occur following malignant transformation.<sup><xref rid="cit0012" ref-type="bibr">12</xref></sup> As such, CD7 is recommended, alongside myeloid associated markers, as a differentiation marker for the assessment of measurable residual disease.<sup><xref rid="cit0013" ref-type="bibr">13</xref>,<xref rid="cit0014" ref-type="bibr">14</xref></sup> The combination of CD7 and CD33 is therefore an appealing target combination for the development of an antibody-based therapeutic to precisely target malignant AML blasts.</p><p>While the development of bispecific ADCs is an emerging trend within the broader ADC landscape, with several candidates currently in clinical development for solid tumor indications,<sup><xref rid="cit0015" ref-type="bibr">15</xref></sup> none have been proposed for hematologic malignancies.<sup><xref rid="cit0015" ref-type="bibr">15</xref></sup> Additionally, most bispecific ADCs under clinical evaluation are designed to engage either target 1 or target 2 individually.</p><p>Here, we introduce BVX001, a first-in-class, affinity-modulated bispecific ADC developed using our <underline>internal</underline> Bi-Cygni&#174; approach. BVX001 is specifically engineered to selectively target leukemic cells, such as AML blasts, by binding <italic toggle="yes">in cis</italic> to cells co-expressing the leukemia-restricted antigen pair CD33 and CD7, a co-expression phenotype largely absent from healthy cells. BVX001&#160;has a rationally designed &#8216;AND-gated&#8217; mechanism, where effective internalization and payload release generally occurs only following dual engagement of both CD33 and CD7. This dual dependency restricts cytotoxic activity to CD33<sup>+</sup> CD7<sup>+</sup> leukemic cells, thereby significantly reducing on-target off-tumor toxicity to single antigen expressing healthy immune cells. In preclinical models of AML, BVX001 demonstrates potent and selective anti-tumor activity, including robust AML blast clearance and anti-leukemic stem cell (LSC) effects in primary patient samples. This affinity-tuned, combinatorial targeting strategy offers a versatile and clinically scalable approach to improve tumor selectivity and therapeutic index, with broad applicability across hematologic and solid malignancies.</p></sec><sec disp-level="1" id="s0002"><title>Materials and methods</title><sec disp-level="2" id="s0002-s2001"><title>Cell lines and primary patient samples</title><p>Cell lines were purchased from DSMZ (Braunschweig, Germany) and cultured according to the supplier&#8217;s recommendations. Bone marrow (BM) AML patient samples were obtained from Cardiff University Biobank UK (REC No 18/SW/0231) or Manchester Cancer Research Centre UK (REC No 22/NW/0237). Additional details are included in the <italic toggle="yes">Supplementary Information</italic>.</p></sec><sec disp-level="2" id="s0002-s2002"><title>Proteomic and transcriptomic data analysis</title><p>Tandem mass tag (TMT) and label-free quantification (LFQ) proteomic datasets from 44 fully characterized The Cancer Genome Atlas (TCGA) AML samples from Kramer et al. <sup><xref rid="cit0016" ref-type="bibr">16</xref></sup> were used. Bulk RNA-seq data from 180 adult cases of <italic toggle="yes">de novo</italic> AML (TCGA LAML dataset)<sup><xref rid="cit0017" ref-type="bibr">17</xref></sup> were retrieved using recount3 R/Bioconductor package.<sup><xref rid="cit0018" ref-type="bibr">18</xref></sup> Uniformly processed gene counts were normalized to trimmed mean of M-values with EdgeR&#8217;s R/Bioconductor package.<sup><xref rid="cit0019" ref-type="bibr">19</xref></sup> Details are included in the <italic toggle="yes">Supplementary Information</italic>.</p></sec><sec disp-level="2" id="s0002-s2003"><title>Flow cytometry</title><p>Flow cytometry (FCM) was performed using MACSQuant16 analyzer (Miltenyi Biotec, Bergisch Gladbach, Germany). The blast gate was defined based on CD45 expression, side-scatter characteristics and quantified as a percentage of total gated events. Additional details are included in the <italic toggle="yes">Supplementary Information</italic>.</p></sec><sec disp-level="2" id="s0002-s2004"><title>Bispecific ADCs</title><p>Binding sequences were cloned and expressed as antibody-binding fragment (Fabs) for purification. The Bi-Cygni&#174; Bi-Fab format (patent WO2019/102234) was generated by derivatizing both Fabs separately using a thiol-maleimide reaction on engineered cysteines within both CH1 domains, before heterodimer Bi-Fab formation by copper-free click chemistry between derivatized Fab proteins. Monomethyl auristatin E (MMAE) or F (MMAF) (<xref rid="f0003" ref-type="fig">Figure 3A</xref>, stars; average DAR4, see supplementary Figure S1A for further details) were covalently attached using maleimide-thiol conjugation to generate BVX001. Details are included in the <italic toggle="yes">Supplementary Information</italic>.</p></sec><sec disp-level="2" id="s0002-s2005"><title>Cytotoxicity assay on cell lines and patient samples</title><p>Cells were seeded into 96-well plates and a 9-point 3-fold ADC dilution (30&#8201;nM &#8722; 4.57 pM) or 4-fold ADC dilution (750&#8201;nM &#8722;11.44 pM) was added. Cells were incubated at 37&#176;C, 5% CO<sub>2</sub> for 96&#8201;hours before WST-1 (Abcam, Cambridge, UK #ab155902) was added and incubated for 3&#8201;hours at 37&#176;C, 5% CO<sub>2</sub>. Absorbance was measured at 440&#8201;nm and 620&#8201;nm, on a SpectramaxAbs microplate reader (Molecular Devices, San Jose, California, United States). Details are included in the <italic toggle="yes">Supplementary Information</italic>.</p></sec><sec disp-level="2" id="s0002-s2006"><title>Humanized mouse model</title><p>The humanized mouse model was established according to and by TransCure BioServices (<ext-link xlink:href="https://transcurebioservices.com/cd34-humanized-mice/" ext-link-type="uri">https://transcurebioservices.com/cd34-humanized-mice/</ext-link>). Details are included in the <italic toggle="yes">Supplementary Information</italic>.</p></sec><sec disp-level="2" id="s0002-s2007"><title>Cell line-derived xenograft</title><p>Model was established by Sygnature Discovery, Nottingham, UK (study: SO1723). SCID mice (CB17/Prkdc SCID) were purchased from Charles River, Wilmington, Massachusetts, United States, and implanted subcutaneously with 5x10<sup>6</sup> HNT-34&#160;human AML cells. Experimental procedures were performed under UK Home Office legislation. Details are included in the <italic toggle="yes">Supplementary Information</italic>.</p></sec><sec disp-level="2" id="s0002-s2008"><title>Long-term culture</title><p>Co-culture experiments were performed as previously described.<sup><xref rid="cit0020" ref-type="bibr">20</xref></sup> Details are included in the <italic toggle="yes">Supplementary Information</italic>.</p></sec><sec disp-level="2" id="s0002-s2009"><title>Patient-derived Xenograft</title><p>Patient-derived xenograft (PDX) models were established by Champions Oncology (Hackensack, New Jersey) (Study: 2347&#8211;107) by IV injecting female NOG-EXL mice (Charles River; Wilmington, Massachusetts) with 2x10<sup>6</sup> primary leukemia cells from a patient. Details are included in the <italic toggle="yes">Supplementary Information</italic>.</p></sec><sec disp-level="2" id="s0002-s2010"><title>Statistical analysis</title><p>The statistical analysis methodology is described in the <italic toggle="yes">Supplementary Information</italic>.</p></sec></sec><sec disp-level="1" id="s0003"><title>Results</title><p>CD33<sup>+</sup>CD7<sup>+</sup> AML represents a poor prognosis subgroup linked to adverse disease characteristics with restricted co-expression on malignant blasts.</p><p>Recent multi-omics studies provide a powerful resource to refine the molecular classification of AML. We analyzed proteomic datasets of 44 AML patients and 6&#160;healthy donor (HD) BM samples.<sup><xref rid="cit0016" ref-type="bibr">16</xref></sup> Most markers that were highly abundant in AML samples were present at similar levels in HD samples. In contrast, CD7 was absent in all 6 HD samples and the combination of CD33 and CD7 was specific to AML, where it was detected in 11.36% of the samples.</p><p>Next, we sought to use transcriptomic datasets to validate this finding in a larger number of samples. We confirmed that the TMT and LFQ proteomic quantification,<sup><xref rid="cit0016" ref-type="bibr">16</xref></sup> presented a strong positive correlation with mRNA abundance for CD33 and CD7 (<xref rid="f0001" ref-type="fig">Figure 1B</xref> and Supplementary Figure S2A). This verification allowed us to analyze the expression of these markers in RNA-seq data from a larger cohort of 126 AML patients from the TCGA.<sup><xref rid="cit0017" ref-type="bibr">17</xref></sup> CD33 and CD7 co-expression was detected in 23% of this cohort (<xref rid="f0001" ref-type="fig">Figure 1C</xref>). However, the co-expression of both antigens was only measurable in 1% of samples in a combined dataset of 18,854 HD tissues. Analysis of single-cell RNA-seq data<sup><xref rid="cit0021" ref-type="bibr">21</xref></sup> confirmed that CD33/CD7 co-expression across multiple cell subpopulations in healthy BM and peripheral blood cells was rare, ranging from 1% to 3% (Supplementary Figure S2B). Together, these results suggest that co-expression of CD33 and CD7 represents a leukemia-specific phenotype restricted to malignant blasts.
<fig position="float" id="f0001" fig-type="figure" orientation="portrait"><label>Figure 1.</label><caption><p>CD7/CD33 co-expressing AML.</p></caption><alt-text>A. Heat map showing the abundance of cluster of differentiation protein in AML patients or healthy donors. B. Plot showing the correlation of CD33 and CD7 mRNA with protein. C. Bubble plot showing expression of CD33 and CD7 bulk mRNA in AML patient samples and normal tissues. D. Heatmap showing molecular features in CD33+/CD7+ AML compared to CD33+/CD7- AML. E. Bar chart showing the percentage of patients which show co-expression of CD33 and CD7 on blasts.</alt-text><alternatives><graphic content-type="color" specific-use="web-only" position="float" orientation="portrait" xlink:href="KMAB_A_2551205_F0001_OC.jpg"/><graphic content-type="black-white" specific-use="print-only" position="float" orientation="portrait" xlink:href="KMAB_A_2551205_F0001_PB.jpg"/></alternatives><attrib>(A) Cluster of differentiation (CD) protein abundance data by LFQ mass spectrometry in 44 adult <italic toggle="yes">de novo</italic> AML patient bone marrow samples and three lineage-depleted and three CD34-selected healthy bone marrow control samples, respectively. (B) CD33 (left) and CD7 (right) protein abundance (TMT) compared to sample-matched transcript levels in bulk RNA sequencing data (in transcript per million: TPM). Pearson correlation test was applied for <italic toggle="yes">n</italic>&#8201;=&#8201;44 AML paired values. Thin black line shows experimentally derived linear regression trend line with 95% confidence band. (C) CD33 versus CD7 Bulk RNA-seq data from 126 adult cases of de novo AML (TCGA, left) and from 18,854&#160;healthy human tissue samples (right). For right panel, multiple healthy tissues and organs from the Developmental Genotype Tissue Expression. GTEx <italic toggle="yes">n</italic>&#8201;=&#8201;17,962 (small bubbles), 152 solid tissue samples, including 11 bone marrow and 17 blood samples from healthy volunteers from the Oncobox Atlas of Normal Tissue Expression (ANTE &#8211; medium bubbles); and 740&#160;healthy tissue samples from TCGA (big bubbles) are shown. Healthy tissue and AML RNAseq data were uniformly processed and normalized to trimmed mean of M-values (TMM). Dotted lines mark the internal threshold set for dual-target expression. (D) Molecular features associated with CD33<sup>+</sup>/CD7<sup>+</sup> AML. Heatmap showing CD33<sup>+</sup>/CD7<sup>+</sup> concomitance of frequently mutated genes in AML (top panel) and genetic and transcriptomic scores, FAB subtype and White Blood Cell Count (WBC, 10<sup>9</sup>/L) (bottom panels). European Leukemia Net (ELN) risk classification. French-American-British (FAB) AML classification. LSC Primed Cycle Quiescent and LSC17 scores from ssGSEA. Patients are classified based on CD33/CD7 co-expression (CD7<sup>+</sup><italic toggle="yes">n</italic>&#8201;=&#8201;29 vs CD7<sup>&#8722;</sup><italic toggle="yes">n</italic>&#8201;=&#8201;151). Comparison between groups was conducted using t-test for numerical variables, Fisher&#8217;s exact test for mutations and Chi-square test for FAB and ELN groups frequency. ns <italic toggle="yes">p</italic>&#8201;&gt;&#8201;0.05. Grey color refers to data that was not determined/available. (E) Percentages of CD33/CD7 co-expressing blasts within CD45-dim SSC-high gated blast population were determined by FCM for 109 AML samples profiled in-house. The percentage of samples above 5% (background) are shown.</attrib></fig></p><p>We compiled data from 20 studies reporting CD7 expression in AML<sup><xref rid="cit0012" ref-type="bibr">12</xref>,<xref rid="cit0022" ref-type="bibr">22&#8211;39</xref></sup> comprising a total of 5,187 patients with AML at diagnosis. Across studies, CD7 was detected on average in 30.2% of AML patients (<xref rid="t0001" ref-type="table">Table 1</xref>). Only 5 of these studies, comprising 759 patients, reported data about CD33 and CD7 co-expression with an average of 22.81%.<sup><xref rid="cit0012" ref-type="bibr">12</xref>,<xref rid="cit0022" ref-type="bibr">22</xref>,<xref rid="cit0025" ref-type="bibr">25</xref>,<xref rid="cit0029" ref-type="bibr">29</xref>,<xref rid="cit0038" ref-type="bibr">38</xref></sup> These reports showed some conflicting observations between studies for clinical features associated with CD7<sup>+</sup> AML (<xref rid="t0001" ref-type="table">Table 1</xref>). Therefore, we compared the clinical and molecular information of 29 CD33<sup>+</sup>CD7<sup>+</sup> AML against 151 CD33<sup>&#177;</sup> CD7<sup>&#8722;</sup> AML from the TCGA dataset based on their transcriptional profile. The frequencies of most mutations were distributed equally in both groups, while CEBPA mutations were significantly enriched in CD33<sup>+</sup>CD7<sup>+</sup> AML (<xref rid="f0001" ref-type="fig">Figure 1D</xref>). No difference in white blood cells nor age was seen in this dataset. However, we found differences in class and prognostic group frequencies. AML is grouped into classes and risk is stratified using the 2017 European LeukemiaNet (ELN17) criteria, based on cell-type maturity and the recommendations for diagnosis and management based on prognostic markers, respectively. The classes that included immature cell types had higher frequency in the CD33<sup>+</sup>CD7<sup>+</sup> AML group than those with more mature cell types. Furthermore, the prognostic group designated by ELN17 criteria was unfavorable for CD33<sup>+</sup>CD7<sup>+</sup> AML.<table-wrap position="float" id="t0001" orientation="portrait"><label>Table 1.</label><caption><p>CD7<sup>+</sup> AML patient data systematic review. CR: complete remission, OS: overall surviuval, DFS: disease free survival, PRS: post-relapse survival.</p></caption><table frame="hsides" rules="groups"><colgroup span="1"><col width="1*" align="left" span="1"/><col width="1*" align="center" span="1"/><col width="1*" align="center" span="1"/></colgroup><thead><tr><th align="left" colspan="1" rowspan="1">&#160;</th><th align="center" colspan="1" rowspan="1">Clinical features</th><th align="center" colspan="1" rowspan="1">Divergent results</th></tr></thead><tbody><tr><td align="left" colspan="1" rowspan="1">WBC (&#8201;&gt;&#8201;50&#8201;&#215;&#8201;10<sup>9</sup>/l)</td><td align="center" colspan="1" rowspan="1">Higher (31,33,38)</td><td align="center" colspan="1" rowspan="1">No difference (22,36)</td></tr><tr><td align="left" colspan="1" rowspan="1">Age</td><td align="center" colspan="1" rowspan="1">Younger (26,36)</td><td align="center" colspan="1" rowspan="1">No difference (9,33)</td></tr><tr><td align="left" colspan="1" rowspan="1">FAB-classification</td><td align="center" colspan="1" rowspan="1">Distinct AML CD7<sup>+</sup> in M0 (22,29,31); M1 (22,29,31); M2(29,33); M4 (33); highest incidence in M5 (29,31,33)</td><td align="center" colspan="1" rowspan="1">Indistinct FAB(34,36)</td></tr><tr><td align="left" colspan="1" rowspan="1">% CD7<sup>+</sup> AML at Diag (Mean; Median; &#177;SD)</td><td align="center" colspan="1" rowspan="1">&#167; 30.2; 32.5; &#177;10.6</td><td align="center" colspan="1" rowspan="1">&#160;</td></tr><tr><td align="left" colspan="1" rowspan="1">CD7 MFI at Diag by FCM</td><td align="center" colspan="1" rowspan="1">Equal repartition of patients with dim moderate bright CD7 expression(23,37)</td><td align="center" colspan="1" rowspan="1">&#160;</td></tr><tr><td align="left" colspan="1" rowspan="1">% CD33+CD7+ AML at Diag (Mean; Median; &#177;SEM)</td><td align="center" colspan="1" rowspan="1">$22.8; 24.6; &#177;13.2(12,22,25,29,38)</td><td align="center" colspan="1" rowspan="1">&#160;</td></tr><tr><td align="left" colspan="1" rowspan="1">Relapse vs Diag % CD7</td><td align="center" colspan="1" rowspan="1">Increase %(12)</td><td align="center" colspan="1" rowspan="1">Decrease %(27)</td></tr><tr><td align="left" colspan="1" rowspan="1">Relapse vs Diag CD7 MFI</td><td align="center" colspan="1" rowspan="1">Increase MFI at relapse(12)</td><td align="center" colspan="1" rowspan="1">&#160;</td></tr><tr><td align="left" colspan="1" rowspan="1">Adverse effect clinical outcome</td><td align="center" colspan="1" rowspan="1">Early death event(38); Lower CR #&#8225;(31) &#8225;(26) #&#8225;(29); shorter OS #&#8225;(31) #&#8225;(29)&#8225;(9); Lower DFS and PRS(36); CD7 independent risk factor(36) #&#8225;(29) &#8225;(9)</td><td align="center" colspan="1" rowspan="1">No differences in CR(34), OS(34,39),EFS(34,39) and in proportion of CD7<sup>+</sup> AML in favorable and adverse risk(12)</td></tr><tr><td align="left" colspan="1" rowspan="1">Cytogenetic</td><td align="center" colspan="1" rowspan="1">t(9;22) (31); chrom 5 and/or 7 anomalies(31); excluded in Trisomy 8(27), Inv16(39) and t(8;21) (39)</td><td align="center" colspan="1" rowspan="1">Normal karyotype(27,29)</td></tr><tr><td align="left" colspan="1" rowspan="1">Molecular/Cytogenetic recurrent Aberrancies</td><td align="center" colspan="1" rowspan="1">CEPBA (double mut) (9,12,39); FLT3-ITD(38); Lower frequency of IDH1mut or IDH2mut (9);MLL rearrangements(31)</td><td align="center" colspan="1" rowspan="1">&#160;</td></tr></tbody></table><table-wrap-foot><fn id="tfn0001"><p>&#167;5187 patients (<italic toggle="yes">n</italic>&#8201;=&#8201;20 studies(9,12,22&#8211;39)); Mean Studies cohort size: 259 patients. $759 patients (<italic toggle="yes">n</italic>&#8201;=&#8201;5 studies(12,22,25,29,38)); #APL included. &#8225; non 7&#8201;+&#8201;3 regimen or multiple regimens applied.</p></fn></table-wrap-foot></table-wrap></p><p>Since some reports associated CD7<sup>+</sup> with an immature phenotype and poor survival (<xref rid="t0001" ref-type="table">Table 1</xref>), we analyzed whether this AML subgroup was enriched in transcriptional signatures associated with LSCs: the 17-gene LSC<sup><xref rid="cit0040" ref-type="bibr">40</xref></sup> and the Cycle-Primed, cycling and quiescent LSC signatures.<sup><xref rid="cit0041" ref-type="bibr">41</xref></sup> We observed that CD33<sup>+</sup>CD7<sup>+</sup> AML was enriched in 17-gene and quiescent LSC scores. Overall, our analysis of the TCGA non-APL AML patient cohort supports that CD33<sup>+</sup>CD7<sup>+</sup> AML constitutes a more immature subgroup with distinct molecular features and poorer clinical outcome.</p><p>Finally, we profiled our own cohort of 109 AML patient samples for CD33/CD7 co-expression using FCM, comprising a mixture of <italic toggle="yes">de novo</italic>, relapsed and refractory patients. CD33/CD7 co-expression on leukemic blasts was found in 31.19% of the patients profiled (<xref rid="f0001" ref-type="fig">Figure 1E</xref>).</p><sec disp-level="2" id="s0003-s2001"><title>Proof-of-concept bispecific ADC selectively targets CD33/CD7 dual expressing cells</title><p>We generated the bispecific BVX001 proof-of-concept ADC, known throughout as BVX001-non tuned (NT), by fusing anti-CD33 Fab1 and anti-CD7 Fab2, to target CD33<sup>+</sup>/CD7<sup>+</sup> co-expressing cells (<xref rid="f0002" ref-type="fig">Figure 2A</xref>). Various antibody formats were compared, including IgG-like, and the Bi-Fab format was found to show superior activity and selectivity to target cells (Supplementary Figure S3A). The linker of the Bi-Fab format showed no stability concern after incubation in rat plasma for up to 4&#8201;days (Supplementary Figure S4A). We screened a panel of cell lines for expression of CD33 and CD7. Kasumi-3 and HNT-34 were both CD33<sup>+</sup>CD7<sup>+</sup>, JURKAT were CD33<sup>&#8722;</sup>CD7<sup>+</sup>, SHI-1 and MV4&#8211;11 were CD33<sup>+</sup>CD7<sup>&#8722;</sup>, and were DND-39 CD33<sup>&#8722;</sup>CD7<sup>&#8722;</sup> (<xref rid="f0002" ref-type="fig">Figure 2B</xref>). BVX001-NT ADC exhibited an IC<sub>50</sub> on target cells several fold lower (6.6&#8211;76.9-fold for Kasumi-3 and 4.8&#8211;56.7-fold for HNT-34) than for non-target single antigen-positive cells (for dose response curve of isotype control, see Supplementary Figure S5A). DND-39 target-negative cells were not sensitive to the highest dose of 30&#8201;nM after 96&#8201;h exposure (<xref rid="f0002" ref-type="fig">Figure 2C</xref>). BVX001-NT bispecific binding was superior to the individual Fabs alone or in combination (<xref rid="f0002" ref-type="fig">Figure 2D</xref>). This suggests that having binding sites to CD33 and CD7 in a single bispecific antibody confers a superior effect, leading to increased binding to double-positive cells.
<fig position="float" id="f0002" fig-type="figure" orientation="portrait"><label>Figure 2.</label><caption><p>Novel bispecific ADC targeting CD33<sup>+</sup>CD7<sup>+</sup> dual antigen expressing AML cells.</p></caption><alt-text>A. Illustration of BVX001 ADC. B. Table showing the number of CD33 or CD7 receptors in the cell line panel used for studies. C. Bar chart showing IC50 values of BVX001-NT. D Bar chart showing binding of BVX001-NT ADC compared to the individual CD33 or CD7 Fabs alone or in combination in double positive KASUMI-3 cells. E. Dose response curves of BVX001-NT in combination with increasing concentrations of a homodimer antibody of CD33 or CD7 in double positive cells or single positive cells. F. Curve showing the internalization rate of BVX001-NT ADC. G. Fluorescent microscope images of double positive cells showing co-localization of BVX001-NT to the lysosome of cells after 24&#160;h.</alt-text><alternatives><graphic content-type="color" specific-use="web-only" position="float" orientation="portrait" xlink:href="KMAB_A_2551205_F0002_OC.jpg"/><graphic content-type="black-white" specific-use="print-only" position="float" orientation="portrait" xlink:href="KMAB_A_2551205_F0002_PB.jpg"/></alternatives><attrib>(A) Schematic of BVX001 ADC. Stars: stochastic conjugation of toxin payload to reduced inter-domain cysteine residues at an average DAR4. See method section. (B) Absolute number (specific antibody-binding capacity: sABC) of CD33 and CD7 antigens on indicated cell lines determined by FCM (<italic toggle="yes">n</italic>&#8201;&#8805;&#8201;7 experiments). (C) Bar chart showing geomean IC<sub>50</sub> values &#177;SD of dual antigen expressing target cells (Kasumi-3 CD33<sup>+</sup>/CD7<sup>+</sup>, HNT-34 CD33<sup>+low</sup>/CD7<sup>+</sup>) and non-target single positive antigen (JURKAT, MV4-11, SHI-1) and non-antigen expressing (DND-39) cells incubated with BVX001-NT for 96&#8201;hours (<italic toggle="yes">n</italic>&#8201;&#8805;&#8201;5). Where values lie at 30&#8201;nM, no IC<sub>50</sub> could be calculated due to no sensitivity of the cells. (D) Binding to double antigen-positive cells of individual Fab arms anti-CD7 or anti-CD33 alone or in combination compared to bispecific BVX001-NT by FCM (<italic toggle="yes">n</italic>&#8201;=&#8201;2). (E) Competition assay. Survival dose response curves of Kasumi-3, SHI-1 or JURKAT cells incubated with BVX001-NT for 96&#8201;hours with the indicated concentration of non-toxin conjugated anti-CD7 or anti-CD33 homodimeric competitor, respectively, added. Thick lines indicate experimentally derived non-linear regression trend lines. (F) Internalization kinetics of payload-free BVX001-NT in Kasumi-3 cells by FCM. Data show the anti-Fab PE MFI (<italic toggle="yes">n</italic>&#8201;=&#8201;3) over time normalized to control anti-Fab PE kept at 4&#176;C. Thick line indicates experimentally derived non-linear regression trend lines. (G) Confocal microscopy of Kasumi-3 incubated with payload-free, Atto488-conjugated BVX001-NT for 0&#8201;hours (left) or 24&#8201;hours (right). BVX001-NT- Atto488 is displayed in green, DNA stained with Hoechst 33,342 is displayed in blue and lysosomes labeled with anti-LAMP1-eFluor660 is displayed in red. Arrows indicate positions of BVX001-NT colocalization in lysosomes (overlayed color: yellow). Scale bar: 15&#8201;&#181;m.</attrib></fig></p><p>Assessment of BVX001-NT&#8217;s cytotoxicity using increasing concentrations of Fab homodimers competing for the targets confirmed that both Fab arms of BVX001-NT were involved and required in the preferential targeting of dual antigen-positive cells (<xref rid="f0002" ref-type="fig">Figure 2E</xref>). Competition with anti CD33 or anti-CD7 homodimer increased the IC<sub>50</sub> of BVX001-NT on Kasumi-3. Conversely, single antigen positive-cells SHI-1 and JURKAT only presented competition effects for the homodimer targeting the expressed antigen in each cell.</p><p>Next, we studied internalization of payload-free fluorophore-labeled BVX001-NT. FCM analysis showed that BVX001-NT disappeared from the plasma membrane following two kinetics, one fast with a T<sub>1/2-fast</sub> of 2.5&#8201;minutes followed by a T<sub>1/2-slow</sub> of 56.0&#8201;minutes (<xref rid="f0002" ref-type="fig">Figure 2F</xref>). Using confocal microscopy, we confirmed that BVX001-NT colocalized with the lysosomal marker LAMP-1 after 24&#8201;h, validating its mechanism of action as an ADC (<xref rid="f0002" ref-type="fig">Figure 2G</xref>). Our data support that BVX001-NT is an obligate bispecific ADC that selectively binds CD33 and CD7 to deliver the sub-nanomolar cytotoxic payload by endocytosis.</p></sec><sec disp-level="2" id="s0003-s2002"><title>Creation of Hu-BVX001, an affinity-optimized AND-gated bispecific ADC that demonstrates potent and selective killing of CD33/CD7 dual-expressing malignant cells.</title><p>We produced a series of six bispecific variants with affinity-tuned anti-CD7 Fabs (<xref rid="f0003" ref-type="fig">Figure 3A</xref>). The variants exhibited different selectivity to double antigen-positive target cell lines versus single-positive and double-negative non-target cell lines (<xref rid="f0003" ref-type="fig">Figure 3B</xref>). Each tested ADC variant was ranked based on the change in selectivity for dual antigen-positive target cells. BVX001, conjugated to vcMMAE displayed an average 29.3&#8201;&#177;&#8201;15.68% increase in selective cell cytotoxicity toward double antigen-positive target Kasumi-3 and HNT-34 cells compared to BVX001-NT (<italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.05) (<xref rid="f0003" ref-type="fig">Figure 3C</xref>). <underline>BVX001 ADC</underline> was selected for further optimization of the linker-payload. Cell permeable vcMMAE can inflict a cytotoxic bystander effect on neighboring healthy cells.<sup><xref rid="cit0042" ref-type="bibr">42&#8211;44</xref></sup> In the context of AML, we deemed the nonspecific bystander effect to be undesirable for BVX001; consequently, the cytotoxin was switched to a non-cleavable, non-cell permeable monomethyl auristatin F (mcMMAF) retaining its target cell selectivity to double antigen-positive cells (<xref rid="f0003" ref-type="fig">Figure 3D</xref>).
<fig position="float" id="f0003" fig-type="figure" orientation="portrait"><label>Figure 3.</label><caption><p>BVX001 optimization.</p></caption><long-desc>Schematic of ADC with affinity tuning of the CD7 Fab. B. Plot showing IC50 values of various BVX001 ADC mutants with affinity modulated CD7 Fab values across a panel of double positive, single positive and double negative cell lines. C. Bar chart showing the percentage change in selectivity of the ADC mutants compared to BVX001-NT. D. Plot showing IC50 values of BVX001 ADC with MMAF or MMAE as a payload in target cells and non-target cells. E. Dose response curve of BVX001 ADC with different linker payloads in HUVEC cell line model to represent macropinocytosis. F. Flow chart showing the process of BVX001-NT CD7 Fab being affinity tuned, payload tuned and humanized to generate Hu-BVX001. G. Plot showing the relative IC50 values of BVX001 compared to Hu-BVX001 ADC in a panel of target and non-target cell lines.</long-desc><alternatives><graphic content-type="color" specific-use="web-only" position="float" orientation="portrait" xlink:href="KMAB_A_2551205_F0003_OC.jpg"/><graphic content-type="black-white" specific-use="print-only" position="float" orientation="portrait" xlink:href="KMAB_A_2551205_F0003_PB.jpg"/></alternatives><attrib>(A) Schematic of BVX001 with anti-CD7 Fab tuning. (B) Comparison of target and non-target cell IC<sub>50</sub> for BVX001 variants with different affinity-tuned anti-CD7 Fab sequences. Data for each condition represent an average of <italic toggle="yes">n</italic>&#8201;&#8805;&#8201;4 experimental repeats. Target cells: Kasumi-3 CD33<sup>+</sup>/CD7<sup>+</sup> and HNT-34 CD33<sup>+low</sup>/CD7<sup>+</sup>; non-target cells: single positive CD33<sup>&#8722;</sup>/CD7<sup>+</sup> (JURKAT) and CD33<sup>+</sup>/CD7<sup>&#8722;</sup> (MV4-11 and SHI-1). (C) Relative target cell selectivity changes as percentage gain or loss compared to BVX001-NT. *: <italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.05 by One-tailed unpaired T-test, (<italic toggle="yes">n</italic>&#8201;&#8805;&#8201;4). (D) Monomethyl auristatin E (MMAE) and F (MMAF) cytotoxic payload comparison. Data show mean IC<sub>50</sub> &#177;SEM of BVX001 conjugated with MMAE or MMAF at a similar average DAR4 for dual-antigen target cells Kasumi-3 and HNT-34 cells and single antigen non-target cells JURKAT MV4-11 and SHI-1. Comparisons were made using an unpaired two-tailed t-test. ns: <italic toggle="yes">p</italic>&#8201;&gt;&#8201;0.05, (<italic toggle="yes">n</italic>&#8201;&#8805;&#8201;5). (E) Survival dose response curves of HUVEC cells treated for 96&#8201;hours with BVX001 conjugated with different cleavable or non-cleavable cytotoxic payloads. Cleavable emtansine (-vcDM1), cleavable MMAF (-vcMMAF), non-cleavable mcMMAF (-mcMMAF). Thick lines show respective experimentally derived non-linear regression trend lines. (F) Flowchart illustrates the affinity, payload tuning and humanization development stages from <underline>BVX001-NT to Hu-BVX001-mcMMAF</underline>. (G) Comparison of IC<sub>50</sub> of Hu-BVX001-mcMMAF and non-humanized BVX001-mcMMAF counterpart in the panel of cell lines. IC<sub>50</sub> of Hu-BVX001-mcMMAF from independent experiments (<italic toggle="yes">n</italic>&#8201;=&#8201;18 to 21) was normalized to the mean IC<sub>50</sub> (from <italic toggle="yes">n</italic>&#8201;=&#8201;41 to 47 experiments) of BVX001-mcMMAF for the same cell line. Dotted horizontal line represents a value of 1, meaning equal IC<sub>50</sub> to BVX001-mcMMAF.</attrib></fig></p><p>Ocular corneal toxicity through macropinocytosis has been reported for ADCs containing MMAF, DM4, and MMAE payloads.<sup><xref rid="cit0045" ref-type="bibr">45</xref></sup> Human umbilical vein endothelial cells (HUVEC), which are CD33 and CD7 negative (Supplementary Figure S6A), exhibit active macropinocytosis and have been previously used as a model system.<sup><xref rid="cit0045" ref-type="bibr">45</xref></sup> We used this system to assess whether BVX001-mcMMAF is prone to nonspecific uptake by this mechanism. Macropinocytosis was confirmed in the model using Belantamab mafodotin as a positive control (Supplementary Figure S6B). Conversely, BVX001 conjugated to non-cleavable mcMMAF, cleavable vcMMAF or cleavable vcDM1 did not show toxicity at up to 30&#8201;nM, well above BVX001 IC<sub>50</sub> on target cells (<xref rid="f0003" ref-type="fig">Figure 3E</xref>). This finding is further supported by the absence of ocular-related histopathological events when Hu-BVX001 was tested in a non-GLP rat toxicity study at repeat doses of&#8201;&lt;&#8201;55&#8201;mg/kg.</p><p>Finally, while the anti-CD33 variable domain of BVX001 was already humanized, the anti-CD7 variable domain originated from an <italic toggle="yes">in vivo</italic> selection in mouse and required humanization (<xref rid="f0003" ref-type="fig">Figure 3F</xref>). From a screening of 28&#160;humanized clones, the most potent variant, Hu-BVX001 showed comparable <italic toggle="yes">in vitro</italic> properties to the parental BVX001 (<xref rid="f0003" ref-type="fig">Figure 3G</xref>) and was selected for further assessment. In addition to comparable <italic toggle="yes">in vitro</italic> properties, Hu-BVX001 also showed greater potency and internalization to Kasumi-3 target cells compared to the individual Fabs when alone or when in combination (Supplementary Figure S7A,C). This data provides further evidence for Hu-BVX001 AND-gated properties.</p></sec><sec disp-level="2" id="s0003-s2003"><title>Hu-BVX001 AND-gated design reduces on-target/off-tissue toxicity</title><p>Hu-BVX001, as an AND-gated bispecific ADC, was rationally designed by affinity modulation to be less toxic to healthy cells that express either CD33 or CD7 alone compared to monospecific ADCs. To prove this principle, we evaluated the effect of Hu-BVX001 on healthy cells expressing either CD33 or CD7. These included CD33<sup>+</sup> myeloid cells and CD7<sup>+</sup> T cells. We analyzed potential myelosuppression induced by Hu-BVX001 using the Colony Forming Unit-Granulocyte-Macrophage (CFU-GM) assay.<sup><xref rid="cit0046" ref-type="bibr">46</xref></sup> Hu-BVX001 did not affect the number of CD33<sup>+</sup> CFU-GM despite continuous exposure over 10&#8201;days at up to 10&#8201;nM, conditions at which GO ADC produced a 100% decrease in <underline>healthy colony formation</underline> (<xref rid="f0004" ref-type="fig">Figure 4A</xref>). Likewise, no appreciable toxicity toward activated CD7<sup>+</sup> T-cells (average CD7 copy number: 95000; in-house validation) was observed over the concentration range of Hu-BVX001 tested. In contrast, anti-CD7 Fab homodimer-mcMMAF ADC induced a 50% loss of viability in T cells at 0.14&#8201;nM (<xref rid="f0004" ref-type="fig">Figure 4B</xref>).
<fig position="float" id="f0004" fig-type="figure" orientation="portrait"><label>Figure 4.</label><caption><p>Hu-BVX001 safety.</p></caption><alt-text>A. Bar chart showing the percentage count of CFU-GM colonies after treatment of CD34+ cord blood samples with Hu-BVX001 ADC compared to Mylotarg&#174;, Gemtuzumab-ozogamicin ADC. B. Dose response curve of Hu-BVX001 ADC compared to anti-CD7 homodimer in T-cells. C. Plots showing the effect of Hu-BVX001 on the BM cell populations in a humanized mouse model. D. Plot comparing the effect of BVX001 ADC to Mylotarg&#174;, Gemtuzumab-ozogamicin on the healthy neutrophil population in a humanized mouse model.</alt-text><alternatives><graphic content-type="color" specific-use="web-only" position="float" orientation="portrait" xlink:href="KMAB_A_2551205_F0004_OC.jpg"/><graphic content-type="black-white" specific-use="print-only" position="float" orientation="portrait" xlink:href="KMAB_A_2551205_F0004_PB.jpg"/></alternatives><attrib>(A) Effect of Hu-BVX001 on healthy cord blood (CB) CD34<sup>+</sup> progenitor cell-derived CD33<sup>+</sup> Colony-forming unit-granulocyte, macrophage (CFU-GM). Data show CFU-GM mean count (&#177;SEM) normalized to the untreated condition at Day 10 (<italic toggle="yes">n</italic>&#8201;=&#8201;3 for Hu-BVX001 ADC and <italic toggle="yes">n</italic>&#8201;=&#8201;2 GO). (B) Survival dose response curves of CD7<sup>+</sup> T cells isolated from PBMC, activated and treated with either Hu-BVX001 or anti-CD7 homodimer DAR-matched ADCs for 96&#8201;h. (C) Mean (&#177;SD) number of healthy hematopoietic BM cells after treatment with Hu-BVX001 at the indicated dose for 2&#8201;weeks. One-way Anova with Dunnett&#8217;s multiple corrections tests was used to compare the treatments groups at D14. All showed no significance. Where no downward error bar is displayed this is due to negative values and axis being logarithmic. (D) Mean (&#177;SEM) number of healthy neutrophils after a single dose of GO or BVX001 (mcMMAF). Data achieved 14&#8201;days after dosing. A one-way Anova and Tukey multiple corrections tests was used to compare the treatments groups at D14, ** <italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.01.</attrib></fig></p><p>The safety of the bispecific ADC was also confirmed in vivo using a humanized mouse model. For Hu-BVX001, doses of 10&#8201;mg/kg and 3&#8201;mg/kg once weekly for 2&#8201;weeks showed no significant change in the number of healthy hematopoietic BM cells, including neutrophils, CD33<sup>+</sup> cells, CD7<sup>+</sup> cells, progenitors and hematopoietic stem cells (<xref rid="f0004" ref-type="fig">Figure 4C</xref>). BVX001 (mcMMAF) ADC was compared to GO which is known to cause neutropenia.<sup><xref rid="cit0007" ref-type="bibr">7</xref></sup> GO led to a significant decrease in the number of neutrophils compared to BVX001 (mcMMAF) ADC, when compared at 0.3&#8201;mg/kg single dose (maximum tolerated dose of GO in mice) (<xref rid="f0004" ref-type="fig">Figure 4D</xref>), an adverse effect which is commonly reported in the clinic.</p><p>Next, we determined the plasma pharmacokinetic profile of Hu-BVX001, which is not mouse cross-reactive, after a single bolus IV injection of 10&#8201;mg/kg in 3 female CD1 mice, a geometric mean T<sub>1/2</sub> of 26.5&#8201;hours was calculated (Supplementary Figure S6C). While the short half-life was expected due to the lack of an Fc-portion, it is anticipated that dosing in the clinic would not exceed once weekly.<sup><xref rid="cit0047" ref-type="bibr">47</xref></sup></p></sec><sec disp-level="2" id="s0003-s2004"><title>Hu-BVX001 causes the effective ablation of CD33/CD7 dual expressing malignant cells in patient samples and tumor models at doses not toxic to normal hematopoietic cells</title><p>The anti-leukemic effect of Hu-BVX001 was tested in patient-derived samples. We assessed the cytotoxic effect of Hu-BVX001 on AML blasts from patient peripheral blood mononuclear cell (PBMC) or BM samples. Where nine double-positive AML samples were tested, eight showed good response to Hu-BVX001 ADC (IC<sub>50</sub> 0.18&#8201;nM &#8722; 104&#8201;nM) (<xref rid="f0005" ref-type="fig">Figure 5A,B</xref>). No major effect was observed for isotype ADC (IC<sub>50</sub> values available in <xref rid="t0002" ref-type="table">Table 2</xref>). One sample did not show a response to Hu-BVX001 ADC (AML 85); however, this sample was less sensitive to MMAE (<xref rid="t0002" ref-type="table">Table 2</xref>), suggesting the patient may have resistance to auristatin-based payloads. The samples that did show a response had a range of CD33<sup>+</sup>/CD7<sup>+</sup> blast percentage (39.6% &#8722;93.1%) and absolute number of receptors in the cell surface (<xref rid="t0002" ref-type="table">Table 2</xref>). This highlights that Hu-BVX001 ADC can target samples with a range of double positivity, including low and high receptors numbers. Additionally, three CD33<sup>+</sup> single-positive samples that were tested showed no response to Hu-BVX001 ADC (Supplementary Figure S8), which confirms the selectivity of Hu-BVX001 ADC to double-positive AML blasts.
<fig position="float" id="f0005" fig-type="figure" orientation="portrait"><label>Figure 5.</label><caption><p>Efficacy of Hu-BVX001 in AML patient samples.</p></caption><alt-text>A. Dot plots from flow cytometry analysis of CD33 and CD7 in four AML PBMC samples along with dose response curve of Hu-BVX001 ADC compared to isotype control in AML PBMC patient samples. B. Dot plots from flow cytometry analysis of CD33 and CD7 in five AML BM samples along with dose response curve of Hu-BVX001 ADC compared to isotype control in AML BM patient samples. C. Schematic of ex vivo study set up where AML BM samples were treated with hu-BVX001 ADC for 3&#8211;4 days and then placed into a limiting dilution assay for long-term culture. D. Bar chart showing the percentage reduction in leukemic long term culture initiating cells in AML BM after treatment with hu-BVX001 ADC.</alt-text><alternatives><graphic content-type="color" specific-use="web-only" position="float" orientation="portrait" xlink:href="KMAB_A_2551205_F0005_OC.jpg"/><graphic content-type="black-white" specific-use="print-only" position="float" orientation="portrait" xlink:href="KMAB_A_2551205_F0005_PB.jpg"/></alternatives><attrib>(A) Flow cytometry plots of AML PBMC samples showing % CD33<sup>+</sup>/CD7<sup>+</sup> co-expression and patient-matched dose response curves for treatment with Hu-BVX001 ADC or Isotype control ADC for 96&#8201;h with IC<sub>50</sub> value displayed. (B) Flow cytometry plots of AML BM samples showing % CD33<sup>+</sup>/CD7<sup>+</sup> co-expression and patient-matched dose response curves for treatment with Hu-BVX001 ADC or Isotype control ADC for 96&#8201;h with IC<sub>50</sub> value displayed. (C) Human primary CD7<sup>+</sup> AML LSC testing procedure for G. CD33<sup>+</sup>CD7<sup>+</sup> AML patient samples (<italic toggle="yes">n</italic>&#8201;=&#8201;7) were incubated with Hu-BVX001 10&#8201;nM for 3 or 4&#8201;days, replated in limiting dilution assay and cultured over 3&#8211;5-week LTC. (D) Percent reduction (&#177;SD) in L-LTC-IC frequencies compared to untreated control after treatment with 10&#8201;nM Hu-BVX001 (see Figure F for experimental set up). ns: <italic toggle="yes">p</italic>&#8201;&gt;&#8201;0.05; *: <italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.05, **: <italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.01, ***: <italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.001. Comparisons were made by ELDA (WEHI, Bioinformatics Division)<sup><xref rid="cit0048" ref-type="bibr">48</xref></sup>.</attrib></fig><table-wrap position="float" id="t0002" orientation="portrait"><label>Table 2.</label><caption><p>AML patient data.</p></caption><table frame="hsides" rules="groups"><colgroup span="1"><col width="1*" align="left" span="1"/><col width="1*" align="left" span="1"/><col width="1*" align="char" char="." span="1"/><col width="1*" align="center" span="1"/><col width="1*" align="center" span="1"/><col width="1*" align="center" span="1"/><col width="1*" align="center" span="1"/><col width="1*" align="center" span="1"/><col width="1*" align="left" span="1"/></colgroup><thead><tr><th align="left" colspan="1" rowspan="1">Sample ID</th><th align="center" colspan="1" rowspan="1">Source</th><th align="center" char="." colspan="1" rowspan="1">% CD33<sup>+</sup>/CD7<sup>+</sup> co- expression</th><th align="center" colspan="1" rowspan="1">CD33 Receptor Number</th><th align="center" colspan="1" rowspan="1">CD7 Receptor Number</th><th align="center" colspan="1" rowspan="1">Hu-BVX001 ADC IC<sub>50</sub> (nM)</th><th align="center" colspan="1" rowspan="1">Isotype Control ADC IC<sub>50</sub> (nM)</th><th align="center" colspan="1" rowspan="1">MMAE IC<sub>50</sub> (nM)</th><th align="center" colspan="1" rowspan="1">Patient Details</th></tr></thead><tbody><tr><td align="left" colspan="1" rowspan="1">AML 67</td><td align="left" colspan="1" rowspan="1">BM</td><td align="char" char="." colspan="1" rowspan="1">93.1</td><td align="center" colspan="1" rowspan="1">10426</td><td align="center" colspan="1" rowspan="1">11260</td><td align="center" colspan="1" rowspan="1">13.2</td><td align="center" colspan="1" rowspan="1">&#8201;&gt;750</td><td align="center" colspan="1" rowspan="1">0.37</td><td align="left" colspan="1" rowspan="1">AML from MDS NPM1mut</td></tr><tr><td align="left" colspan="1" rowspan="1">AML 3882</td><td align="left" colspan="1" rowspan="1">PBMC</td><td align="char" char="." colspan="1" rowspan="1">92.9</td><td align="center" colspan="1" rowspan="1">ND</td><td align="center" colspan="1" rowspan="1">ND</td><td align="center" colspan="1" rowspan="1">0.19</td><td align="center" colspan="1" rowspan="1">246</td><td align="center" colspan="1" rowspan="1">ND</td><td align="left" colspan="1" rowspan="1">Na&#239;ve AML FLT3 WT</td></tr><tr><td align="left" colspan="1" rowspan="1">AML 3674</td><td align="left" colspan="1" rowspan="1">PBMC</td><td align="char" char="." colspan="1" rowspan="1">73.2</td><td align="center" colspan="1" rowspan="1">ND</td><td align="center" colspan="1" rowspan="1">ND</td><td align="center" colspan="1" rowspan="1">2.97</td><td align="center" colspan="1" rowspan="1">770</td><td align="center" colspan="1" rowspan="1">ND</td><td align="left" colspan="1" rowspan="1">Na&#239;ve AML FLT-3mut non ITD</td></tr><tr><td align="left" colspan="1" rowspan="1">AML 4052</td><td align="left" colspan="1" rowspan="1">PBMC</td><td align="char" char="." colspan="1" rowspan="1">58.2</td><td align="center" colspan="1" rowspan="1">ND</td><td align="center" colspan="1" rowspan="1">ND</td><td align="center" colspan="1" rowspan="1">104</td><td align="center" colspan="1" rowspan="1">532</td><td align="center" colspan="1" rowspan="1">ND</td><td align="left" colspan="1" rowspan="1">Na&#239;ve AML IDH1 mut FLT3mut non ITD</td></tr><tr><td align="left" colspan="1" rowspan="1">AML 163</td><td align="left" colspan="1" rowspan="1">BM</td><td align="char" char="." colspan="1" rowspan="1">55.8</td><td align="center" colspan="1" rowspan="1">19067</td><td align="center" colspan="1" rowspan="1">10181</td><td align="center" colspan="1" rowspan="1">19.9</td><td align="center" colspan="1" rowspan="1">&#8201;&gt;750</td><td align="center" colspan="1" rowspan="1">0.17</td><td align="left" colspan="1" rowspan="1">AML from CMML NPM1mut</td></tr><tr><td align="left" colspan="1" rowspan="1">AML 62</td><td align="left" colspan="1" rowspan="1">BM</td><td align="char" char="." colspan="1" rowspan="1">48.5</td><td align="center" colspan="1" rowspan="1">4393</td><td align="center" colspan="1" rowspan="1">3294</td><td align="center" colspan="1" rowspan="1">1.23</td><td align="center" colspan="1" rowspan="1">&#8201;&gt;750</td><td align="center" colspan="1" rowspan="1">0.53</td><td align="left" colspan="1" rowspan="1">AML from MDS/MPN</td></tr><tr><td align="left" colspan="1" rowspan="1">AML 85</td><td align="left" colspan="1" rowspan="1">BM</td><td align="char" char="." colspan="1" rowspan="1">48.5</td><td align="center" colspan="1" rowspan="1">7109</td><td align="center" colspan="1" rowspan="1">3767</td><td align="center" colspan="1" rowspan="1">&#8201;&gt;750</td><td align="center" colspan="1" rowspan="1">&#8201;&gt;750</td><td align="center" colspan="1" rowspan="1">12.71</td><td align="left" colspan="1" rowspan="1">Relapsed AML</td></tr><tr><td align="left" colspan="1" rowspan="1">AML 161</td><td align="left" colspan="1" rowspan="1">BM</td><td align="char" char="." colspan="1" rowspan="1">42.4</td><td align="center" colspan="1" rowspan="1">20503</td><td align="center" colspan="1" rowspan="1">5195</td><td align="center" colspan="1" rowspan="1">14</td><td align="center" colspan="1" rowspan="1">583</td><td align="center" colspan="1" rowspan="1">0.48</td><td align="left" colspan="1" rowspan="1">Na&#239;ve AML NPM1mut</td></tr><tr><td align="left" colspan="1" rowspan="1">AML 2456</td><td align="left" colspan="1" rowspan="1">PBMC</td><td align="char" char="." colspan="1" rowspan="1">39.6</td><td align="center" colspan="1" rowspan="1">ND</td><td align="center" colspan="1" rowspan="1">ND</td><td align="center" colspan="1" rowspan="1">6.1</td><td align="center" colspan="1" rowspan="1">356</td><td align="center" colspan="1" rowspan="1">ND</td><td align="left" colspan="1" rowspan="1">Na&#239;ve AML Del<sup><xref rid="cit0007" ref-type="bibr">7</xref></sup> FLT3 WT</td></tr><tr><td align="left" colspan="1" rowspan="1">AML 120</td><td align="left" colspan="1" rowspan="1">BM</td><td align="char" char="." colspan="1" rowspan="1">4.7</td><td align="center" colspan="1" rowspan="1">9812</td><td align="center" colspan="1" rowspan="1">2724</td><td align="center" colspan="1" rowspan="1">&#8201;&gt;750</td><td align="center" colspan="1" rowspan="1">&#8201;&gt;750</td><td align="center" colspan="1" rowspan="1">1.74</td><td align="left" colspan="1" rowspan="1">AML from MDS</td></tr><tr><td align="left" colspan="1" rowspan="1">AML 132</td><td align="left" colspan="1" rowspan="1">BM</td><td align="char" char="." colspan="1" rowspan="1">4.2</td><td align="center" colspan="1" rowspan="1">30320</td><td align="center" colspan="1" rowspan="1">1553</td><td align="center" colspan="1" rowspan="1">&#8201;&gt;750</td><td align="center" colspan="1" rowspan="1">ND</td><td align="center" colspan="1" rowspan="1">1.37</td><td align="left" colspan="1" rowspan="1">AML from CMML NPM1mut FLT-3 mut</td></tr><tr><td align="left" colspan="1" rowspan="1">AML 25</td><td align="left" colspan="1" rowspan="1">BM</td><td align="char" char="." colspan="1" rowspan="1">2</td><td align="center" colspan="1" rowspan="1">6153</td><td align="center" colspan="1" rowspan="1">999</td><td align="center" colspan="1" rowspan="1">494</td><td align="center" colspan="1" rowspan="1">&#8201;&gt;750</td><td align="center" colspan="1" rowspan="1">0.27</td><td align="left" colspan="1" rowspan="1">Na&#239;ve AML</td></tr></tbody></table></table-wrap></p><p>In addition to the blast-killing effect and considering the transcriptional enrichment in LSC signatures observed in patients with CD33<sup>+</sup>CD7<sup>+</sup> blasts (<xref rid="f0001" ref-type="fig">Figure 1D</xref>), we questioned whether Hu-BVX001 could affect the LSC activity associated with this AML subgroup. To address this question, we conducted a LTC assay on primary patient samples (<xref rid="f0005" ref-type="fig">Figure 5C</xref>). This assay showed Hu-BVX001 induced a reduction of 71.31&#8201;&#177;&#8201;8.84% (mean &#177;SEM) in the frequency of leukemic long-term culture-initiating cells (L-LTC-IC) compared to untreated control samples (<xref rid="f0005" ref-type="fig">Figure 5D</xref>). We did not observe a correlation between the percentage of CD33<sup>+</sup>CD7<sup>+</sup> blasts in each sample before treatment and the anti-L-LTC-IC effect of Hu-BVX001 (Supplementary Figure S8B), suggesting patients with as low as 20% double-positive blasts may benefit from treatment.</p><p>The anti-leukemic efficacy of Hu-BVX001 was further assessed <italic toggle="yes">in vivo</italic> in HNT-34 (CD33<sup>+low</sup>/CD7<sup>+</sup>) xenografts. The low level of CD33 expression makes this cell line challenging to treat with monospecific anti-CD33 ADC (Supplementary Figure S9A) and emulates the blast heterogeneity often found in patients with AML. The first experiment was designed to evaluate the effect of Hu-BVX001 on the growth of subcutaneous tumors. Hu-BVX001 dosed at 10&#8201;mg/kg twice weekly was compared to SoC high-dose cytarabine (HiDAC) administered at the maximum tolerated dose of 20&#8201;mg/kg 5&#8201;days on/2&#8201;days off. Treatment began when HNT-34 mean tumor volume reached 0.2&#8201;cm<sup>3</sup> and continued for 4&#8201;weeks (<xref rid="f0006" ref-type="fig">Figure 6A</xref>). Hu-BVX001 treatment resulted in 100% tumor growth inhibition and 93% tumor regression on day 28 while HiDAC treatment resulted in 100% tumor growth inhibition and 87% tumor regression (<xref rid="f0006" ref-type="fig">Figure 6B</xref>). However, a sequential comparison of tumor sizes showed that the effect on tumor volume of Hu-BVX001 was stronger than that of HiDAC on days 5, 8, 12, 15, 19 and 22 (Supplementary Figure S9B). Hu-BVX001 was well tolerated, and no adverse effects were observed throughout the dosing period. The survival of mice was monitored after treatment cessation, showing a survival benefit for the HiDAC and Hu-BVX001 groups over control (HiDAC: <italic toggle="yes">p</italic>&#8201;=&#8201;0.0007, Hu-BVX001: <italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.0001) (<xref rid="f0006" ref-type="fig">Figure 6C</xref>). Moreover, the mice receiving Hu-BVX001 had significantly longer survival than the HiDAC treated group (<italic toggle="yes">p</italic>&#8201;=&#8201;0.0212) with a median survival of 129&#8201;days for Hu-BVX001 compared to 91&#8201;days for HiDAC and 57&#8201;days for the control group.
<fig position="float" id="f0006" fig-type="figure" orientation="portrait"><label>Figure 6.</label><caption><p>In vivo therapeutic efficacy of Hu-BVX001.</p></caption><long-desc>A. Schematic of study set up for in vivo CLDX study. Images of mice being injected with cells and then injected with test articles when the tumor volume is 0.2cm3. B. Plots showing tumor volume of mice that have been treated with vehicle control, HiDAC or Hi-BVX001 ADC. C. Kaplan Meier plot showing survival of mice after treatment with either vehicle control, HiDAC or Hu-BVX001 ADC. D. Schematic of study set up for CLDX study using larger tumor size model. Mice are injected with cells and then with test article when tumor volume reached 0.7cm3. E. Plot showing tumor volume after treatment with vehicle or Hu-BVX001 ADC where initial tumor volume was larger. F. Schematic of PDX study where mice are injected with cells and 20% hCD45 cells were detected before injecting with test article. G. Plots showing the effect of Hu-BVX001 or isotype control on CD33+/CD7+ events compared to vehicle control in 2 PDX models.</long-desc><alternatives><graphic content-type="color" specific-use="web-only" position="float" orientation="portrait" xlink:href="KMAB_A_2551205_F0006_OC.jpg"/><graphic content-type="black-white" specific-use="print-only" position="float" orientation="portrait" xlink:href="KMAB_A_2551205_F0006_PB.jpg"/></alternatives><attrib>(A) Subcutaneous xenograft SCID mouse design for B-C. SCID mice were implanted with 5x10<sup>6</sup> HNT-34 cells. Mice were treated with vehicle twice weekly for 4&#8201;weeks or with Cytarabine 20&#8201;mg/kg 5&#8201;days on/2&#8201;days off for 4&#8201;weeks or with Hu-BVX001 at 10&#8201;mg/kg twice weekly for 4&#8201;weeks. (B) Tumor growth curves. Shaded areas indicate continuous daily treatment, dotted lines indicate single injections. Each symbol represents a single recipient (<italic toggle="yes">n</italic>&#8201;=&#8201;12/group for control <italic toggle="yes">n</italic>&#8201;=&#8201;11/group for HiDAC, <italic toggle="yes">n</italic>&#8201;=&#8201;9/group for Hu-BVX001 ADC). nt&#8201;=&#8201;no tumor, nm&#8201;=&#8201;non-measurable tumor. (C) Survival of HNT-34 xenograft study shown in A and B. Data analysis by log-rank Mantel-Cox&#8217;s test. Dotted line indicates the cessation of treatments. *: <italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.05, ***: <italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.001, ****: <italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.0001. (D) Experimental design for E. HNT-34 tumors were allowed to grow to 0.7&#8201;cm<sup>3</sup> before treatment with Hu-BVX001. (E) Mean (&#177;SD) tumor volume in mice treated with Hu-BVX001 at 10&#8201;mg/kg twice per week for 4&#8201;weeks (purple circle; <italic toggle="yes">n</italic>&#8201;=&#8201;6) or vehicle control (open triangle; <italic toggle="yes">n</italic>&#8201;=&#8201;12) from day 33. Vehicle control group monitoring was stopped at day 47 due to tumor size. nm&#8201;=&#8201;non-measurable tumor. (F) Experimental design of PDX models for G. ~20% engraftment was detected before treatment with Hu-BVX001 or isotype control. (G) Mean (&#177;SD) number of CD33<sup>+</sup>/CD7<sup>+</sup> blasts remaining after treatment with Hu-BVX001 or isotype control at the indicated doses for 4&#8201;weeks. A one-way Anova with Tukey multiple comparison test was used to compare all groups to one another ***<italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.001 and ****<italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.0001.</attrib></fig></p><p>In a second experiment, we investigated the effect of Hu-BVX001 on larger established tumors (<xref rid="f0006" ref-type="fig">Figure 6D</xref>). HNT-34 tumors were allowed to reach ca. 0.7&#8201;cm<sup>3</sup> volume before starting Hu-BVX001 treatment following the same dosage as previously. Hu-BVX001 group showed a significant 100% tumor growth inhibition and 97% tumor regression (<xref rid="f0006" ref-type="fig">Figure 6D</xref>). Five out of six treated mice had non-measurable tumors or no tumor at the end of treatment. Remarkably, Hu-BVX001 extended the median survival of these mice with established large tumors to 151&#8201;days (<italic toggle="yes">p</italic>&#8201;=&#8201;0.0015) (Supplementary Figure S9C).</p><p>The efficacy of Hu-BVX001 was examined in two PDX models, CTG-3882, from a homogenous CD33<sup>+</sup>/CD7<sup>+</sup> donor, and CTG-2456, from a heterogenous CD33<sup>+</sup>/CD7<sup>+</sup> donor. In both models Hu-BVX001 led to a significant reduction in total blast burden by decreasing the number of CD33<sup>+</sup>/CD7<sup>+</sup> blasts at doses that were not toxic to healthy hematopoietic cells (<xref rid="f0004" ref-type="fig">Figure 4A</xref>). Furthermore, when dosed in combination with clinically relevant doses of the SoC combination regimen Ven/Aza<sup><xref rid="cit0049" ref-type="bibr">49</xref></sup> across two CD33<sup>+</sup>/CD7<sup>+</sup> AML cell lines, Hu-BVX001 was able to further reduce cell viability beyond Ven/Aza alone, highlighting a potential additive effect of the triplicate regimen for CD33<sup>+</sup>/CD7<sup>+</sup> AML patients (Supplementary Figure S9D).</p><p>Our data suggest that targeting CD33 and CD7 with the Hu-BVX001 bispecific ADC provides high cancer-cell selectivity with a desirable safety profile on healthy cells while effectively targeting CD33<sup>+</sup>CD7<sup>+</sup> AML blasts. Moreover, Hu-BVX001 induced durable tumor regressions <italic toggle="yes">in vivo</italic>, had potent AML blast killing activity, and targeted leukemic stem progenitor cells.</p></sec></sec><sec disp-level="1" id="s0004"><title>Discussion</title><p>In line with previous reports,<sup><xref rid="cit0012" ref-type="bibr">12</xref></sup> our FCM profiling shows that co-expression of CD33 and CD7 is found at diagnosis and in relapsed or refractory disease in 31.19% of patients with AML, while this combination is rarely present on healthy cells. Intriguingly, our analysis also shows that CD7<sup>+</sup> AML is associated with an immature phenotype and unfavorable risk, as determined by ELN17, in agreement with results from a recent independent analysis of a large cohort of 901 AML patients.<sup><xref rid="cit0009" ref-type="bibr">9</xref></sup> Moreover, we provide evidence supporting that CD7<sup>+</sup> AML constitutes a molecularly distinct subgroup and is enriched in LSC transcriptomic signatures. In agreement with the hypothesis that CD7<sup>+</sup> AML constitutes an aggressive subgroup, CD7&#160;has recently been reported to be an independent predictor of shorter overall survival<sup><xref rid="cit0009" ref-type="bibr">9</xref></sup> and refractory response to ven/HMA regimens in AML.<sup><xref rid="cit0010" ref-type="bibr">10</xref></sup> To address this poorer prognosis AML subpopulation, we developed and characterized the bispecific ADC Hu-BVX001. Hu-BVX001 was rationally designed through affinity modulation to eliminate the problematic CD33<sup>+</sup>/CD7<sup>+</sup> malignant cells while eliminating on-targetoff-tumor toxicity in healthy cells that express these markers individually. We show that Hu-BVX001 can selectively target CD33<sup>+</sup>CD7<sup>+</sup> AML cells over single positive or double negative non-target cells. These markers are expressed individually by healthy myeloid and lymphoid cells, but the co-expression of CD33/CD7 is limited to malignant blasts. Additionally, we observed that 34.1% of MDS BM samples showed CD33<sup>+</sup>/CD7<sup>+</sup> co-expression (Supplementary Figure S10A). Therefore, Hu-BVX001 could offer a highly effective targeted therapeutic option with a wide therapeutic window for this aggressive AML subtype which represents an urgent unmet need with the opportunity to expand to other key indications. To prove this concept, we characterized the potential toxicity on healthy human CD33<sup>+</sup> myeloid and CD7<sup>+</sup> T cells. Hu-BVX001 did not show toxicity to primary myeloid cells nor T cells at concentrations at which toxicity was observed for monospecific anti-CD33 or anti-CD7 ADC counterparts. Hu-BVX001 also showed no toxicity to normal hematopoietic cells in a humanized mouse model, whereas GO showed a significant reduction in the number of normal neutrophils compared to Hu-BVX001 (mcMMAF). This suggests that Hu-BVX001 may provide the potential to reduce the onset of neutropenia leading to infection and neutropenic sepsis, which is often fatal in AML patients.</p><p>Moreover, Hu-BVX001 also exhibited a favorable safety profile regarding ocular toxicity, a common off-target/off-tissue effect of ADCs conjugated to auristatin payloads like MMAF.<sup><xref rid="cit0045" ref-type="bibr">45</xref></sup> Toxicity remains a persistent drawback of ADCs in the clinic, with clinical trials reporting an incidence of 46.1% for serious adverse effects (grade 3 or higher).<sup><xref rid="cit0050" ref-type="bibr">50</xref></sup> Data presented here suggest that bispecific ADCs, such as those developed using the Bi-Cygni&#174; approach, can improve cancer-cell selectivity as well as the safety profile of future ADC therapies.</p><p>In addition to an improved safety profile, our results show that Hu-BVX001 can induce durable tumor regressions and superior survival benefits in relevant CD33<sup>+</sup>/CD7<sup>+</sup> AML xenograft models compared to SoC at doses close to the maximum-tolerated dose in this model. Furthermore, Hu-BVX001 was able to cause significant tumor regressions in this low antigen-expressing &#8216;hard-to-treat&#8217; model of AML, where monospecific CD33 targeted ADCs did not show an impact <italic toggle="yes">in vitro</italic>. Importantly, Hu-BVX001-induced durable responses in both small and more established tumors. Hu-BVX001 also had a potent killing effect on CD33<sup>+</sup>/CD7<sup>+</sup> AML blasts in patient samples presenting a range of target expression and frequency of CD33<sup>+</sup>/CD7<sup>+</sup> blasts. Furthermore, we suggest that Hu-BVX001 can also target the LSC compartment in AML, consistently with the increased stemness characteristics of CD33<sup>+</sup>CD7<sup>+</sup> AML. We show that Hu-BVX001 has a meaningful impact on the LSC compartment, responsible for relapse, in patient samples with as few as 20% double-positive blast cells. Hu-BVX001 also showed a significant decrease in tumor burden in AML PDX models at doses which showed no toxicity to healthy hematopoietic cells, in a humanized mouse model. Hu-BVX001 successfully depleted CD33<sup>+</sup>/CD7<sup>+</sup> blasts across both homogeneous and heterogenous AML models. Hu-BVX001 has been shown to effectively and selectively cause the potent ablation of CD33<sup>+</sup>CD7<sup>+</sup> malignant blasts, and LSCs, which could have benefits in the clinical setting as a monotherapy or as a potential combination therapy with Ven/Aza to improve outcomes for patients with CD33<sup>+</sup>CD7<sup>+</sup> AML.</p><p>In summation, we show that through utilizing our Bi-Cygni&#174; approach, the resultant AND-gated bispecific ADCs can deliver potent anti-cancer activity, even within challenging and heterogenous patient populations, with the potential for a much wider therapeutic window.</p></sec><sec sec-type="supplementary-material"><title>Supplementary Material</title><supplementary-material id="SM5063" position="float" content-type="local-data" orientation="portrait"><caption><title>Supplementary_Text_Griffiths_et_al_final_version.docx</title></caption><media xlink:href="KMAB_A_2551205_SM5063.docx" position="float" orientation="portrait"/></supplementary-material><supplementary-material id="SM5062" position="float" content-type="local-data" orientation="portrait"><caption><title>Figure S3.jpg</title></caption><media xlink:href="KMAB_A_2551205_SM5062.jpg" position="float" orientation="portrait"/></supplementary-material><supplementary-material id="SM5061" position="float" content-type="local-data" orientation="portrait"><caption><title>Figure S5.jpg</title></caption><media xlink:href="KMAB_A_2551205_SM5061.jpg" position="float" orientation="portrait"/></supplementary-material><supplementary-material id="SM5060" position="float" content-type="local-data" orientation="portrait"><caption><title>Figure S6.jpg</title></caption><media xlink:href="KMAB_A_2551205_SM5060.jpg" position="float" orientation="portrait"/></supplementary-material><supplementary-material id="SM5059" position="float" content-type="local-data" orientation="portrait"><caption><title>Figure S2.jpg</title></caption><media xlink:href="KMAB_A_2551205_SM5059.jpg" position="float" orientation="portrait"/></supplementary-material><supplementary-material id="SM5058" position="float" content-type="local-data" orientation="portrait"><caption><title>Figure S10.jpg</title></caption><media xlink:href="KMAB_A_2551205_SM5058.jpg" position="float" orientation="portrait"/></supplementary-material><supplementary-material id="SM5057" position="float" content-type="local-data" orientation="portrait"><caption><title>Figure S1.jpg</title></caption><media xlink:href="KMAB_A_2551205_SM5057.jpg" position="float" orientation="portrait"/></supplementary-material><supplementary-material id="SM5056" position="float" content-type="local-data" orientation="portrait"><caption><title>Figure S8.jpg</title></caption><media xlink:href="KMAB_A_2551205_SM5056.jpg" position="float" orientation="portrait"/></supplementary-material><supplementary-material id="SM5055" position="float" content-type="local-data" orientation="portrait"><caption><title>Figure S4.jpg</title></caption><media xlink:href="KMAB_A_2551205_SM5055.jpg" position="float" orientation="portrait"/></supplementary-material><supplementary-material id="SM5054" position="float" content-type="local-data" orientation="portrait"><caption><title>Figure S7.jpg</title></caption><media xlink:href="KMAB_A_2551205_SM5054.jpg" position="float" orientation="portrait"/></supplementary-material><supplementary-material id="SM5053" position="float" content-type="local-data" orientation="portrait"><caption><title>Figure S9.jpg</title></caption><media xlink:href="KMAB_A_2551205_SM5053.jpg" position="float" orientation="portrait"/></supplementary-material></sec></body><back><ack><title>Acknowledgments</title><p>The authors would like to thank: Sygnature Discovery, Sygnature Discovery Limited, The Discovery Building, BioCity, Pennyfoot Street, Nottingham NG1 1GR; SixthResearcher c/o Alvaro Sebastian-Yag&#252;e, Dolna Wilda 6A/18, 61-552 Pozna&#324;, Poland; Champions Oncology, Hackensack, New Jersey.</p></ack><sec disp-level="1" id="s0005"><title>Author contributions</title><p>Experimental studies and data analysis: HG, NJ, MV, NF, EM, NNA, MM, CP, EG. Study design HG, EM, NJ, EG, OS, TDT. Manuscript writing and editing: EG, HG, ABG, TDT. All authors contributed to the final version of the manuscript.</p></sec><sec disp-level="1" id="s0006"><title>Data-sharing statement</title><p>The data that support the findings of this study are available upon request from the corresponding author.</p></sec><sec sec-type="COI-statement" disp-level="1" id="s0007"><title>Disclosure statement</title><p>TDT is the inventor of a patent portfolio related to this work. Other authors have no conflicts of interest to disclose.</p></sec><sec sec-type="supplementary-material" disp-level="1" id="s0008"><title>Supplementary material</title><p>Supplemental data for this article can be accessed online at <ext-link xlink:href="https://doi.org/10.1080/19420862.2025.2551205" ext-link-type="uri">https://doi.org/10.1080/19420862.2025.2551205</ext-link>.</p></sec><ref-list><title>References</title><ref id="cit0001"><label>1.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Estey</surname><given-names>EH.</given-names></string-name></person-group><article-title>Acute myeloid leukemia: 2021 update on risk&#8208;stratification and management</article-title>. <source>Am J Hematol</source>. <year>2020</year>; <volume>95</volume>(<issue>11</issue>):<fpage>1368</fpage>&#8211;<lpage>17</lpage>. doi: <pub-id pub-id-type="doi">10.1002/ajh.25975</pub-id>.<pub-id pub-id-type="pmid">32833263</pub-id></mixed-citation></ref><ref id="cit0002"><label>2.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Siegel</surname><given-names>RL</given-names></string-name>, <string-name name-style="western"><surname>Miller</surname><given-names>KD</given-names></string-name>, <string-name name-style="western"><surname>Jemal</surname><given-names>A</given-names></string-name></person-group>. <article-title>Cancer statistics, 2019</article-title>. <source>CA Cancer J Clin</source>. <year>2019</year>; <volume>69</volume>(<issue>1</issue>):<fpage>7</fpage>&#8211;<lpage>34</lpage>. doi: <pub-id pub-id-type="doi">10.3322/caac.21551</pub-id>.<pub-id pub-id-type="pmid">30620402</pub-id></mixed-citation></ref><ref id="cit0003"><label>3.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Pollyea</surname><given-names>DA</given-names></string-name>, <string-name name-style="western"><surname>Bixby</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Perl</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Bhatt</surname><given-names>VR</given-names></string-name>, <string-name name-style="western"><surname>Altman</surname><given-names>JK</given-names></string-name>, <string-name name-style="western"><surname>Appelbaum</surname><given-names>FR</given-names></string-name>, <string-name name-style="western"><surname>de Lima</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Fathi</surname><given-names>AT</given-names></string-name>, <string-name name-style="western"><surname>Foran</surname><given-names>JM</given-names></string-name>, <string-name name-style="western"><surname>Gojo</surname><given-names>I</given-names></string-name>, et al</person-group>. <article-title>NCCN guidelines insights: acute myeloid leukemia, version 2.2021</article-title>. <source>J Educ Chang National Comprehensive Cancer Network</source>. <year>2021</year>; <volume>19</volume>(<issue>1</issue>):<fpage>16</fpage>&#8211;<lpage>27</lpage>. doi: <pub-id pub-id-type="doi">10.6004/jnccn.2021.0002</pub-id>.<pub-id pub-id-type="pmid">33406488</pub-id></mixed-citation></ref><ref id="cit0004"><label>4.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Griffiths</surname><given-names>EA</given-names></string-name>, <string-name name-style="western"><surname>Carraway</surname><given-names>HE</given-names></string-name>, <string-name name-style="western"><surname>Chandhok</surname><given-names>NS</given-names></string-name>, <string-name name-style="western"><surname>Prebet</surname><given-names>T</given-names></string-name></person-group>. <article-title>Advances in non-intensive chemotherapy treatment options for adults diagnosed with acute myeloid leukemia</article-title>. <source>Leuk Res</source>. <year>2020</year>; <volume>91</volume>:<fpage>106339</fpage>. doi: <pub-id pub-id-type="doi">10.1016/j.leukres.2020.106339</pub-id>.<pub-id pub-id-type="pmid">32146154</pub-id></mixed-citation></ref><ref id="cit0005"><label>5.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Abaza</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Fathi</surname><given-names>AT</given-names></string-name></person-group>. <article-title>Monoclonal antibodies in acute myeloid leukemia&#8212;are we there yet?</article-title><source>Cancer J</source>. <year>2022</year>; <volume>28</volume>(<issue>1</issue>):<fpage>37</fpage>&#8211;<lpage>42</lpage>. doi: <pub-id pub-id-type="doi">10.1097/PPO.0000000000000577</pub-id>.<pub-id pub-id-type="pmid">35072372</pub-id></mixed-citation></ref><ref id="cit0006"><label>6.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Parslow</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Parakh</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Lee</surname><given-names>FT</given-names></string-name>, <string-name name-style="western"><surname>Gan</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Scott</surname><given-names>A</given-names></string-name></person-group>. <article-title>Antibody&#8211;drug conjugates for cancer therapy</article-title>. <source>Biomedicines</source>. <year>2016</year>; <volume>4</volume>(<issue>3</issue>):<fpage>14</fpage>. doi: <pub-id pub-id-type="doi">10.3390/biomedicines4030014</pub-id>.<pub-id pub-id-type="pmid">28536381</pub-id><pub-id pub-id-type="pmcid">PMC5344263</pub-id></mixed-citation></ref><ref id="cit0007"><label>7.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Cortes</surname><given-names>JE</given-names></string-name>, <string-name name-style="western"><surname>de Lima</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Dombret</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Estey</surname><given-names>EH</given-names></string-name>, <string-name name-style="western"><surname>Giralt</surname><given-names>SA</given-names></string-name>, <string-name name-style="western"><surname>Montesinos</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>R&#246;llig</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Venditti</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Wang</surname><given-names>ES</given-names></string-name></person-group>. <article-title>Prevention, recognition, and management of adverse events associated with gemtuzumab ozogamicin use in acute myeloid leukemia</article-title>. <source>J Hematol Oncol</source>. <year>2020</year>; <volume>13</volume>(<issue>1</issue>):<fpage>137</fpage>. doi: <pub-id pub-id-type="doi">10.1186/s13045-020-00975-2</pub-id>.<pub-id pub-id-type="pmid">33059764</pub-id><pub-id pub-id-type="pmcid">PMC7559451</pub-id></mixed-citation></ref><ref id="cit0008"><label>8.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Pelosi</surname><given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Castelli</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Testa</surname><given-names>U</given-names></string-name></person-group>. <article-title>CD123 a therapeutic target for acute myeloid leukemia and blastic plasmocytoid dendritic neoplasm</article-title>. <source>Int J Mol Sci</source>. <year>2023</year>; <volume>24</volume>(<issue>3</issue>):<fpage>2718</fpage>. doi: <pub-id pub-id-type="doi">10.3390/ijms24032718</pub-id>.<pub-id pub-id-type="pmid">36769040</pub-id><pub-id pub-id-type="pmcid">PMC9917129</pub-id></mixed-citation></ref><ref id="cit0009"><label>9.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Jen</surname><given-names>WY</given-names></string-name>, <string-name name-style="western"><surname>Sasaki</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Loghavi</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Wang</surname><given-names>SA</given-names></string-name>, <string-name name-style="western"><surname>Qiao</surname><given-names>W</given-names></string-name>, <string-name name-style="western"><surname>Borthakur</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Ravandi</surname><given-names>F</given-names></string-name>, <string-name name-style="western"><surname>Kadia</surname><given-names>TM</given-names></string-name>, <string-name name-style="western"><surname>Issa</surname><given-names>GC</given-names></string-name>, <string-name name-style="western"><surname>Short</surname><given-names>NJ</given-names></string-name>, et al</person-group>. <article-title>Characteristics and outcomes of acute myeloid leukaemia patients with baseline CD7 expression</article-title>. <source>Br J Haematol</source>. <year>2024</year>; <volume>204</volume>(<issue>6</issue>):<fpage>2259</fpage>&#8211;<lpage>2263</lpage>. doi: <pub-id pub-id-type="doi">10.1111/bjh.19446</pub-id>.<pub-id pub-id-type="pmid">38603594</pub-id><pub-id pub-id-type="pmcid">PMC11770636</pub-id></mixed-citation></ref><ref id="cit0010"><label>10.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Islam</surname><given-names>N</given-names></string-name>, <string-name name-style="western"><surname>Reuben</surname><given-names>JS</given-names></string-name>, <string-name name-style="western"><surname>Dale</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Gutman</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>McMahon</surname><given-names>CM</given-names></string-name>, <string-name name-style="western"><surname>Amaya</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Goodman</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Toninato</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Gasparetto</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Stevens</surname><given-names>B</given-names></string-name>, et al</person-group>. <article-title>Machine learning&#8211;based exploratory clinical decision support for newly diagnosed patients with acute myeloid leukemia treated with 7 + 3 type chemotherapy or Venetoclax/Azacitidine</article-title>. <source>JCO Clin Cancer Inf</source>. <year>2022</year>; (<issue>6</issue>). doi: <pub-id pub-id-type="doi">10.1200/CCI.22.00030</pub-id>.<pub-id pub-id-type="pmid">36194842</pub-id></mixed-citation></ref><ref id="cit0011"><label>11.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Lv</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Cai</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Chen</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Xu</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Wan</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Zhou</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Du</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Ma</surname><given-names>X</given-names></string-name>, <string-name name-style="western"><surname>Wu</surname><given-names>X</given-names></string-name>, <string-name name-style="western"><surname>Tang</surname><given-names>X</given-names></string-name>, et al</person-group>. <article-title>Prognostic value of lymphoid marker CD7 expression in acute myeloid leukemia patients undergoing allogeneic hematopoietic cell transplantation in first morphological complete remission</article-title>. <source>Int J Hematol</source>. <year>2021</year>; <volume>114</volume>(<issue>4</issue>):<fpage>464</fpage>&#8211;<lpage>471</lpage>. doi: <pub-id pub-id-type="doi">10.1007/s12185-021-03182-y</pub-id>.<pub-id pub-id-type="pmid">34176091</pub-id></mixed-citation></ref><ref id="cit0012"><label>12.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Haubner</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Perna</surname><given-names>F</given-names></string-name>, <string-name name-style="western"><surname>K&#246;hnke</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Schmidt</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Berman</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Augsberger</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Schnorfeil</surname><given-names>FM</given-names></string-name>, <string-name name-style="western"><surname>Krupka</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Lichtenegger</surname><given-names>FS</given-names></string-name>, <string-name name-style="western"><surname>Liu</surname><given-names>X</given-names></string-name>, et al</person-group>. <article-title>Coexpression profile of leukemic stem cell markers for combinatorial targeted therapy in AML</article-title>. <source>Leukemia</source> [Internet]. <year>2019</year>;<volume>33</volume>(<issue>1</issue>):<fpage>64</fpage>&#8211;<lpage>74</lpage>. doi: <pub-id pub-id-type="doi">10.1038/s41375-018-0180-3</pub-id>.<pub-id pub-id-type="pmid">29946192</pub-id><pub-id pub-id-type="pmcid">PMC6326956</pub-id></mixed-citation></ref><ref id="cit0013"><label>13.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Schuurhuis</surname><given-names>GJ</given-names></string-name>, <string-name name-style="western"><surname>Heuser</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Freeman</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>B&#233;n&#233;</surname><given-names>MC</given-names></string-name>, <string-name name-style="western"><surname>Buccisano</surname><given-names>F</given-names></string-name>, <string-name name-style="western"><surname>Cloos</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Grimwade</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Haferlach</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Hills</surname><given-names>RK</given-names></string-name>, <string-name name-style="western"><surname>Hourigan</surname><given-names>CS</given-names></string-name>, et al</person-group>. <article-title>Minimal/measurable residual disease in AML: a consensus document from the European LeukemiaNet MRD working party</article-title>. <source>Blood</source>. <year>2018</year>; <volume>131</volume>(<issue>12</issue>):<fpage>1275</fpage>&#8211;<lpage>1291</lpage>. doi: <pub-id pub-id-type="doi">10.1182/blood-2017-09-801498</pub-id>.<pub-id pub-id-type="pmid">29330221</pub-id><pub-id pub-id-type="pmcid">PMC5865231</pub-id></mixed-citation></ref><ref id="cit0014"><label>14.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Ossenkoppele</surname><given-names>GJ</given-names></string-name>, <string-name name-style="western"><surname>van de Loosdrecht</surname><given-names>AA</given-names></string-name>, <string-name name-style="western"><surname>Schuurhuis</surname><given-names>GJ</given-names></string-name></person-group>. <article-title>Review of the relevance of aberrant antigen expression by flow cytometry in myeloid neoplasms</article-title>. <source>Br J Haematol</source>. <year>2011</year>;<volume>153</volume>(<issue>4</issue>):<fpage>421</fpage>&#8211;<lpage>436</lpage>. doi: <pub-id pub-id-type="doi">10.1111/j.1365-2141.2011.08595.x</pub-id>.<pub-id pub-id-type="pmid">21385170</pub-id></mixed-citation></ref><ref id="cit0015"><label>15.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Gu</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Wang</surname><given-names>Z</given-names></string-name>, <string-name name-style="western"><surname>Wang</surname><given-names>Y</given-names></string-name></person-group>. <article-title>Bispecific antibody drug conjugates: making 1+1&gt;2</article-title>. <source>Acta Pharm Sin B [Internet]</source>. <year>2024</year><month>May</month><day>1</day> [<date-in-citation>cited 2025 <month>Apr</month><day>24</day></date-in-citation>];<volume>14</volume>(<issue>5</issue>):<fpage>1965</fpage>. <ext-link xlink:href="https://pmc.ncbi.nlm.nih.gov/articles/PMC11119582/" ext-link-type="uri">https://pmc.ncbi.nlm.nih.gov/articles/PMC11119582/</ext-link>.<pub-id pub-id-type="pmid">38799638</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.apsb.2024.01.009</pub-id><pub-id pub-id-type="pmcid">PMC11119582</pub-id></mixed-citation></ref><ref id="cit0016"><label>16.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Kramer</surname><given-names>MH</given-names></string-name>, <string-name name-style="western"><surname>Zhang</surname><given-names>Q</given-names></string-name>, <string-name name-style="western"><surname>Sprung</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Day</surname><given-names>RB</given-names></string-name>, <string-name name-style="western"><surname>Erdmann-Gilmore</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Li</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Xu</surname><given-names>Z</given-names></string-name>, <string-name name-style="western"><surname>Helton</surname><given-names>NM</given-names></string-name>, <string-name name-style="western"><surname>George</surname><given-names>DR</given-names></string-name>, <string-name name-style="western"><surname>Mi</surname><given-names>Y</given-names></string-name>, et al</person-group>. <article-title>Proteomic and phosphoproteomic landscapes of acute myeloid leukemia</article-title>. <source>Blood</source>. <year>2022</year>; <volume>140</volume>(<issue>13</issue>):<fpage>1533</fpage>&#8211;<lpage>1548</lpage>. doi: <pub-id pub-id-type="doi">10.1182/blood.2022016033</pub-id>.<pub-id pub-id-type="pmid">35895896</pub-id><pub-id pub-id-type="pmcid">PMC9523374</pub-id></mixed-citation></ref><ref id="cit0017"><label>17.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><collab>The Cancer Genome Atlas Research Network</collab></person-group>. <article-title>Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia</article-title>. <source>N Engl J Med</source>. <year>2013</year>; <volume>368</volume>(<issue>22</issue>):<fpage>2059</fpage>&#8211;<lpage>2074</lpage>. doi: <pub-id pub-id-type="doi">10.1056/NEJMoa1301689</pub-id>.<pub-id pub-id-type="pmid">23634996</pub-id><pub-id pub-id-type="pmcid">PMC3767041</pub-id></mixed-citation></ref><ref id="cit0018"><label>18.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Wilks</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Zheng</surname><given-names>SC</given-names></string-name>, <string-name name-style="western"><surname>Chen</surname><given-names>FY</given-names></string-name>, <string-name name-style="western"><surname>Charles</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Solomon</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Ling</surname><given-names>JP</given-names></string-name>, <string-name name-style="western"><surname>Imada</surname><given-names>EL</given-names></string-name>, <string-name name-style="western"><surname>Zhang</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Joseph</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Leek</surname><given-names>JT</given-names></string-name>, et al</person-group>. <article-title>Recount3: summaries and queries for large-scale RNA-seq expression and splicing</article-title>. <source>Genome Biol</source>. <year>2021</year>; <volume>22</volume>(<issue>1</issue>):<fpage>323</fpage>. doi: <pub-id pub-id-type="doi">10.1186/s13059-021-02533-6</pub-id>.<pub-id pub-id-type="pmid">34844637</pub-id><pub-id pub-id-type="pmcid">PMC8628444</pub-id></mixed-citation></ref><ref id="cit0019"><label>19.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Robinson</surname><given-names>MD</given-names></string-name>, <string-name name-style="western"><surname>McCarthy</surname><given-names>DJ</given-names></string-name>, <string-name name-style="western"><surname>Smyth</surname><given-names>GK</given-names></string-name></person-group>. <article-title>EdgeR: a Bioconductor package for differential expression analysis of digital gene expression data</article-title>. <source>Bioinformatics</source>. <year>2010</year>; <volume>26</volume>(<issue>1</issue>):<fpage>139</fpage>&#8211;<lpage>140</lpage>. doi: <pub-id pub-id-type="doi">10.1093/bioinformatics/btp616</pub-id>.<pub-id pub-id-type="pmid">19910308</pub-id><pub-id pub-id-type="pmcid">PMC2796818</pub-id></mixed-citation></ref><ref id="cit0020"><label>20.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Griessinger</surname><given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Anjos-Afonso</surname><given-names>F</given-names></string-name>, <string-name name-style="western"><surname>Pizzitola</surname><given-names>I</given-names></string-name>, <string-name name-style="western"><surname>Rouault-Pierre</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Vargaftig</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Taussig</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Gribben</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Lassailly</surname><given-names>F</given-names></string-name>, <string-name name-style="western"><surname>Bonnet</surname><given-names>D</given-names></string-name></person-group>. <article-title>A niche-like culture system allowing the maintenance of primary human acute myeloid leukemia-initiating cells: a new tool to decipher their chemoresistance and self-renewal mechanisms</article-title>. <source>STEM Cells Transl Med</source>. <year>2014</year>; <volume>3</volume>(<issue>4</issue>):<fpage>520</fpage>&#8211;<lpage>529</lpage>. doi: <pub-id pub-id-type="doi">10.5966/sctm.2013-0166</pub-id>.<pub-id pub-id-type="pmid">24493855</pub-id><pub-id pub-id-type="pmcid">PMC3973718</pub-id></mixed-citation></ref><ref id="cit0021"><label>21.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Xie</surname><given-names>X</given-names></string-name>, <string-name name-style="western"><surname>Liu</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Zhang</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Wang</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Zhu</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Wang</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Li</surname><given-names>Q</given-names></string-name>, <string-name name-style="western"><surname>Huo</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Guo</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Xu</surname><given-names>C</given-names></string-name>, et al</person-group>. <article-title>Single-cell transcriptomic landscape of human blood cells</article-title>. <source>Natl Sci Rev</source>. <year>2021</year>;<volume>8</volume>(<issue>3</issue>). doi: <pub-id pub-id-type="doi">10.1093/nsr/nwaa180</pub-id>.<pub-id pub-id-type="pmcid">PMC8288407</pub-id><pub-id pub-id-type="pmid">34691592</pub-id></mixed-citation></ref><ref id="cit0022"><label>22.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Coco</surname><given-names>FL</given-names></string-name>, <string-name name-style="western"><surname>Rossi</surname><given-names>GD</given-names></string-name>, <string-name name-style="western"><surname>Pasqualetti</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Lopez</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Diverio</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Latagliata</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Fenu</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Mandelli</surname><given-names>F</given-names></string-name></person-group>. <article-title>CD7 positive acute myeloid leukaemia: a subtype associated with cell immaturity</article-title>. <source>Br J Haematol</source>. <year>1989</year>; <volume>73</volume>(<issue>4</issue>):<fpage>480</fpage>&#8211;<lpage>485</lpage>. doi: <pub-id pub-id-type="doi">10.1111/j.1365-2141.1989.tb00284.x</pub-id>.<pub-id pub-id-type="pmid">2482063</pub-id></mixed-citation></ref><ref id="cit0023"><label>23.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Terstappen</surname><given-names>LW</given-names></string-name>, <string-name name-style="western"><surname>Safford</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>K&#246;nemann</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Loken</surname><given-names>MR</given-names></string-name>, <string-name name-style="western"><surname>Zurlutter</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>B&#252;chner</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Hiddemann</surname><given-names>W</given-names></string-name>, <string-name name-style="western"><surname>W&#246;rmann</surname><given-names>B</given-names></string-name></person-group>. <article-title>Flow cytometric characterization of acute myeloid leukemia. Part II. Phenotypic heterogeneity at diagnosis</article-title>. <source>Leukemia</source>. <year>1992</year>; <volume>6</volume>(<issue>1</issue>):<fpage>70</fpage>&#8211;<lpage>80</lpage>.<pub-id pub-id-type="pmid">1540262</pub-id></mixed-citation></ref><ref id="cit0024"><label>24.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Cuneo</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Michaux</surname><given-names>JL</given-names></string-name>, <string-name name-style="western"><surname>Ferrant</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Van Hove</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Bosly</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Stul</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Dal Cin</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Vandenberghe</surname><given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Cassiman</surname><given-names>JJ</given-names></string-name>, <string-name name-style="western"><surname>Negrini</surname><given-names>M</given-names></string-name></person-group>. <article-title>Correlation of cytogenetic patterns and clinicobiological features in adult acute myeloid leukemia expressing lymphoid markers</article-title>. <source>Blood</source>. <year>1992</year>; <volume>79</volume>(<issue>3</issue>):<fpage>720</fpage>&#8211;<lpage>727</lpage>. doi: <pub-id pub-id-type="doi">10.1182/blood.V79.3.720.720</pub-id>.<pub-id pub-id-type="pmid">1732012</pub-id></mixed-citation></ref><ref id="cit0025"><label>25.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Eto</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Akashi</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Harada</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Shibuya</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Takamatsu</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Teshima</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Niho</surname><given-names>Y</given-names></string-name></person-group>. <article-title>Biological characteristics of CD7 positive acute myelogenous leukaemia</article-title>. <source>Br J Haematol</source>. <year>1992</year>; <volume>82</volume>(<issue>3</issue>):<fpage>508</fpage>&#8211;<lpage>514</lpage>. doi: <pub-id pub-id-type="doi">10.1111/j.1365-2141.1992.tb06460.x</pub-id>.<pub-id pub-id-type="pmid">1283077</pub-id></mixed-citation></ref><ref id="cit0026"><label>26.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Kita</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Miwa</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Nakase</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Kawakami</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Kobayashi</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Shirakawa</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Tanaka</surname><given-names>I</given-names></string-name>, <string-name name-style="western"><surname>Ohta</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Tsutani</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Oguma</surname><given-names>S</given-names></string-name></person-group>. <article-title>Clinical importance of CD7 expression in acute myelocytic leukemia. The Japan Cooperative Group of Leukemia/Lymphoma</article-title>. <source>Blood</source>. <year>1993</year>; <volume>81</volume>(<issue>9</issue>):<fpage>2399</fpage>&#8211;<lpage>2405</lpage>. doi: <pub-id pub-id-type="doi">10.1182/blood.V81.9.2399.2399</pub-id>.<pub-id pub-id-type="pmid">7683218</pub-id></mixed-citation></ref><ref id="cit0027"><label>27.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Reading</surname><given-names>CL</given-names></string-name>, <string-name name-style="western"><surname>Estey</surname><given-names>EH</given-names></string-name>, <string-name name-style="western"><surname>Huh</surname><given-names>YO</given-names></string-name>, <string-name name-style="western"><surname>Claxton</surname><given-names>DF</given-names></string-name>, <string-name name-style="western"><surname>Sanchez</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Terstappen</surname><given-names>LW</given-names></string-name>, <string-name name-style="western"><surname>O&#8217;Brien</surname><given-names>MC</given-names></string-name>, <string-name name-style="western"><surname>Baron</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Deisseroth</surname><given-names>AB</given-names></string-name></person-group>. <article-title>Expression of unusual immunophenotype combinations in acute myelogenous leukemia</article-title>. <source>Blood</source>. <year>1993</year>; <volume>81</volume>(<issue>11</issue>):<fpage>3083</fpage>&#8211;<lpage>3090</lpage>. doi: <pub-id pub-id-type="doi">10.1182/blood.V81.11.3083.3083</pub-id>.<pub-id pub-id-type="pmid">8499643</pub-id></mixed-citation></ref><ref id="cit0028"><label>28.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Kornblau</surname><given-names>SM</given-names></string-name>, <string-name name-style="western"><surname>Thall</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Huh</surname><given-names>YO</given-names></string-name>, <string-name name-style="western"><surname>Estey</surname><given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Andreeff</surname><given-names>M</given-names></string-name></person-group>. <article-title>Analysis of CD7 expression in acute myelogenous leukemia: martingale residual plots combined with &#8220;optimal&#8221; cutpoint analysis reveals absence of prognostic significance</article-title>. <source>Leukemia</source>. <year>1995</year>; <volume>9</volume>(<issue>10</issue>):<fpage>1735</fpage>&#8211;<lpage>1741</lpage>.<pub-id pub-id-type="pmid">7564518</pub-id></mixed-citation></ref><ref id="cit0029"><label>29.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Poeta</surname><given-names>GD</given-names></string-name>, <string-name name-style="western"><surname>Stasi</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Venditti</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Cox</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Aronica</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Masi</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Bruno</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Simone</surname><given-names>MD</given-names></string-name>, <string-name name-style="western"><surname>Buccisano</surname><given-names>F</given-names></string-name>, <string-name name-style="western"><surname>Papa</surname><given-names>G</given-names></string-name></person-group>. <article-title>Cd7 expression in acute myeloid leukemia a</article-title>. <source>Leuk Lymphoma</source>. <year>1995</year>; <volume>17</volume>(<issue>1&#8211;2</issue>):<fpage>111</fpage>&#8211;<lpage>119</lpage>. doi: <pub-id pub-id-type="doi">10.3109/10428199509051710</pub-id>.<pub-id pub-id-type="pmid">7539657</pub-id></mixed-citation></ref><ref id="cit0030"><label>30.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Miwa</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Nakase</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Kita</surname><given-names>K</given-names></string-name></person-group>. <article-title>Biological characteristics of CD7(+) acute leukemia</article-title>. <source>Leuk Lymphoma</source>. <year>1996</year>; <volume>21</volume>(<issue>3&#8211;4</issue>):<fpage>239</fpage>&#8211;<lpage>244</lpage>.<pub-id pub-id-type="pmid">8726405</pub-id></mixed-citation></ref><ref id="cit0031"><label>31.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Venditti</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Poeta</surname><given-names>GD</given-names></string-name>, <string-name name-style="western"><surname>Buccisano</surname><given-names>F</given-names></string-name>, <string-name name-style="western"><surname>Tamburini</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Cox-Froncillo</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Aronica</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Bruno</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Moro</surname><given-names>BD</given-names></string-name>, <string-name name-style="western"><surname>Epiceno</surname><given-names>AM</given-names></string-name>, <string-name name-style="western"><surname>Battaglia</surname><given-names>A</given-names></string-name>, et al</person-group>. <article-title>Prognostic relevance of the expression of TDT and CD7 in 335 cases of acute myeloid leukemia</article-title>. <source>Leukemia</source>. <year>1998</year>; <volume>12</volume>(<issue>7</issue>):<fpage>1056</fpage>&#8211;<lpage>1063</lpage>. doi: <pub-id pub-id-type="doi">10.1038/sj.leu.2401067</pub-id>.<pub-id pub-id-type="pmid">9665190</pub-id></mixed-citation></ref><ref id="cit0032"><label>32.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Casasnovas</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Campos</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Mugneret</surname><given-names>F</given-names></string-name>, <string-name name-style="western"><surname>Charrin</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>B&#233;n&#233;</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Garand</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Favre</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Sartiaux</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Chaumarel</surname><given-names>I</given-names></string-name>, <string-name name-style="western"><surname>Bernier</surname><given-names>M</given-names></string-name></person-group>. et al. <article-title>Immunophenotypic patterns and cytogenetic anomalies in acute non-lymphoblastic leukemia subtypes: a prospective study of 432 patients</article-title>. <source>Leukemia</source>. <year>1998</year>; <volume>12</volume>(<issue>1</issue>):<fpage>34</fpage>&#8211;<lpage>43</lpage>. doi: <pub-id pub-id-type="doi">10.1038/sj.leu.2400893</pub-id>.<pub-id pub-id-type="pmid">9436918</pub-id></mixed-citation></ref><ref id="cit0033"><label>33.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Legrand</surname><given-names>O</given-names></string-name>, <string-name name-style="western"><surname>Perrot</surname><given-names>JY</given-names></string-name>, <string-name name-style="western"><surname>Baudard</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Cordier</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Lautier</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Simonin</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Zittoun</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Casadevall</surname><given-names>N</given-names></string-name>, <string-name name-style="western"><surname>Marie</surname><given-names>J-P</given-names></string-name></person-group>. et al. <article-title>The immunophenotype of 177 adults with acute myeloid leukemia: proposal of a prognostic score</article-title>. <source>Blood</source>. <year>2000</year>; <volume>96</volume>(<issue>3</issue>):<fpage>870</fpage>&#8211;<lpage>877</lpage>. doi: <pub-id pub-id-type="doi">10.1182/blood.V96.3.870</pub-id>.<pub-id pub-id-type="pmid">10910899</pub-id></mixed-citation></ref><ref id="cit0034"><label>34.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Chang</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Salma</surname><given-names>F</given-names></string-name>, <string-name name-style="western"><surname>Yi</surname><given-names>Q-L</given-names></string-name>, <string-name name-style="western"><surname>Patterson</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Brien</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Minden</surname><given-names>MD</given-names></string-name></person-group>. <article-title>Prognostic relevance of immunophenotyping in 379 patients with acute myeloid leukemia</article-title>. <source>Leuk Res</source>. <year>2004</year>; <volume>28</volume>(<issue>1</issue>):<fpage>43</fpage>&#8211;<lpage>48</lpage>. doi: <pub-id pub-id-type="doi">10.1016/S0145-2126(03)00180-2</pub-id>.<pub-id pub-id-type="pmid">14630079</pub-id></mixed-citation></ref><ref id="cit0035"><label>35.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Cruse</surname><given-names>JM</given-names></string-name>, <string-name name-style="western"><surname>Lewis</surname><given-names>RE</given-names></string-name>, <string-name name-style="western"><surname>Pierce</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Lam</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Tadros</surname><given-names>Y</given-names></string-name></person-group>. <article-title>Aberrant expression of CD7, CD56, and CD79a antigens in acute myeloid leukemias</article-title>. <source>Exp Mol Pathol</source>. <year>2005</year>; <volume>79</volume>(<issue>1</issue>):<fpage>39</fpage>&#8211;<lpage>41</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.yexmp.2005.02.003</pub-id>.<pub-id pub-id-type="pmid">16005710</pub-id></mixed-citation></ref><ref id="cit0036"><label>36.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Chang</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Yeung</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Brandwein</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Yi</surname><given-names>Q-L</given-names></string-name></person-group>. <article-title>CD7 expression predicts poor disease free survival and post-remission survival in patients with acute myeloid leukemia and normal karyotype a</article-title>. <source>Leuk Res</source>. <year>2007</year>. <volume>31</volume>(<issue>2</issue>):<fpage>157</fpage>&#8211;<lpage>162</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.leukres.2006.06.001</pub-id>.<pub-id pub-id-type="pmid">16837044</pub-id></mixed-citation></ref><ref id="cit0037"><label>37.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Lewis</surname><given-names>RE</given-names></string-name>, <string-name name-style="western"><surname>Cruse</surname><given-names>JM</given-names></string-name>, <string-name name-style="western"><surname>Sanders</surname><given-names>CM</given-names></string-name>, <string-name name-style="western"><surname>Webb</surname><given-names>RN</given-names></string-name>, <string-name name-style="western"><surname>Suggs</surname><given-names>JL</given-names></string-name></person-group>. <article-title>Aberrant expression of T-cell markers in acute myeloid leukemia</article-title>. <source>Exp Mol Pathol</source>. <year>2007</year>; <volume>83</volume>(<issue>3</issue>):<fpage>462</fpage>&#8211;<lpage>463</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.yexmp.2007.08.010</pub-id>.<pub-id pub-id-type="pmid">17927977</pub-id></mixed-citation></ref><ref id="cit0038"><label>38.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Rausei-Mills</surname><given-names>V</given-names></string-name>, <string-name name-style="western"><surname>Chang</surname><given-names>KL</given-names></string-name>, <string-name name-style="western"><surname>Gaal</surname><given-names>KK</given-names></string-name>, <string-name name-style="western"><surname>Weiss</surname><given-names>LM</given-names></string-name>, <string-name name-style="western"><surname>Huang</surname><given-names>Q</given-names></string-name></person-group>. <article-title>Aberrant expression of CD7 in myeloblasts is highly associated with de novo acute myeloid leukemias with FLT3/ITD mutation</article-title>. <source>Am J Clin Pathol</source>. <year>2008</year>; <volume>129</volume>(<issue>4</issue>):<fpage>624</fpage>&#8211;<lpage>629</lpage>. doi: <pub-id pub-id-type="doi">10.1309/NRTX9AKXHR5JBT93</pub-id>.<pub-id pub-id-type="pmid">18343790</pub-id></mixed-citation></ref><ref id="cit0039"><label>39.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>van Solinge</surname><given-names>TS</given-names></string-name>, <string-name name-style="western"><surname>Zeijlemaker</surname><given-names>W</given-names></string-name>, <string-name name-style="western"><surname>Ossenkoppele</surname><given-names>GJ</given-names></string-name>, <string-name name-style="western"><surname>Cloos</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Schuurhuis</surname><given-names>GJ</given-names></string-name></person-group>. <article-title>The interference of genetic associations in establishing the prognostic value of the immunophenotype in acute myeloid leukemia a</article-title>. <source>Cytometry B Clin Cytom</source>. <year>2018</year>; <volume>94</volume>(<issue>1</issue>):<fpage>151</fpage>&#8211;<lpage>158</lpage>. doi: <pub-id pub-id-type="doi">10.1002/cyto.b.21539</pub-id>.<pub-id pub-id-type="pmid">28646564</pub-id></mixed-citation></ref><ref id="cit0040"><label>40.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Ng</surname><given-names>SWK</given-names></string-name>, <string-name name-style="western"><surname>Mitchell</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Kennedy</surname><given-names>JA</given-names></string-name>, <string-name name-style="western"><surname>Chen</surname><given-names>WC</given-names></string-name>, <string-name name-style="western"><surname>McLeod</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Ibrahimova</surname><given-names>N</given-names></string-name>, <string-name name-style="western"><surname>Arruda</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Popescu</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Gupta</surname><given-names>V</given-names></string-name>, <string-name name-style="western"><surname>Schimmer</surname><given-names>AD</given-names></string-name>, et al</person-group>. <article-title>A 17-gene stemness score for rapid determination of risk in acute leukaemia</article-title>. <source>Nature</source>. <year>2016</year>; <volume>540</volume>(<issue>7633</issue>):<fpage>433</fpage>&#8211;<lpage>437</lpage>. doi: <pub-id pub-id-type="doi">10.1038/nature20598</pub-id>.<pub-id pub-id-type="pmid">27926740</pub-id></mixed-citation></ref><ref id="cit0041"><label>41.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Zeng</surname><given-names>AGX</given-names></string-name>, <string-name name-style="western"><surname>Bansal</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Jin</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Mitchell</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Chen</surname><given-names>WC</given-names></string-name>, <string-name name-style="western"><surname>Abbas</surname><given-names>HA</given-names></string-name>, <string-name name-style="western"><surname>Chan-Seng-Yue</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Voisin</surname><given-names>V</given-names></string-name>, <string-name name-style="western"><surname>van Galen</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Tierens</surname><given-names>A</given-names></string-name>, et al</person-group>. <article-title>A cellular hierarchy framework for understanding heterogeneity and predicting drug response in acute myeloid leukemia</article-title>. <source>Nat Med</source>. <year>2022</year>; <volume>28</volume>(<issue>6</issue>):<fpage>1212</fpage>&#8211;<lpage>1223</lpage>. doi: <pub-id pub-id-type="doi">10.1038/s41591-022-01819-x</pub-id>.<pub-id pub-id-type="pmid">35618837</pub-id></mixed-citation></ref><ref id="cit0042"><label>42.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Chalouni</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Doll</surname><given-names>S</given-names></string-name></person-group>. <article-title>Fate of antibody-drug conjugates in cancer cells</article-title>. <source>J Exp Clin Cancer Res</source>. <year>2018</year>; <volume>37</volume>(<issue>1</issue>):<fpage>20</fpage>. doi: <pub-id pub-id-type="doi">10.1186/s13046-017-0667-1</pub-id>.<pub-id pub-id-type="pmid">29409507</pub-id><pub-id pub-id-type="pmcid">PMC5802061</pub-id></mixed-citation></ref><ref id="cit0043"><label>43.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Ha</surname><given-names>SYY</given-names></string-name>, <string-name name-style="western"><surname>Anami</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Yamazaki</surname><given-names>CM</given-names></string-name>, <string-name name-style="western"><surname>Xiong</surname><given-names>W</given-names></string-name>, <string-name name-style="western"><surname>Haase</surname><given-names>CM</given-names></string-name>, <string-name name-style="western"><surname>Olson</surname><given-names>SD</given-names></string-name>, <string-name name-style="western"><surname>Lee</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Ueno</surname><given-names>NT</given-names></string-name>, <string-name name-style="western"><surname>Zhang</surname><given-names>N</given-names></string-name>, <string-name name-style="western"><surname>An</surname><given-names>Z</given-names></string-name>, et al</person-group>. <article-title>An enzymatically cleavable tripeptide linker for maximizing the therapeutic index of antibody&#8211;drug conjugates</article-title>. <source>Mol Cancer Ther</source>. <year>2022</year>; <volume>21</volume>(<issue>9</issue>):<fpage>1449</fpage>&#8211;<lpage>1461</lpage>. doi: <pub-id pub-id-type="doi">10.1158/1535-7163.MCT-22-0362</pub-id>.<pub-id pub-id-type="pmid">35793453</pub-id><pub-id pub-id-type="pmcid">PMC9452487</pub-id></mixed-citation></ref><ref id="cit0044"><label>44.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Staudacher</surname><given-names>AH</given-names></string-name>, <string-name name-style="western"><surname>Brown</surname><given-names>MP</given-names></string-name></person-group>. <article-title>Antibody drug conjugates and bystander killing: is antigen-dependent internalisation required?</article-title><source>Br J Cancer</source>. <year>2017</year>; <volume>117</volume>(<issue>12</issue>):<fpage>1736</fpage>&#8211;<lpage>1742</lpage>. doi: <pub-id pub-id-type="doi">10.1038/bjc.2017.367</pub-id>.<pub-id pub-id-type="pmid">29065110</pub-id><pub-id pub-id-type="pmcid">PMC5729478</pub-id></mixed-citation></ref><ref id="cit0045"><label>45.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Zhao</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Atkinson</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Gulesserian</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Zeng</surname><given-names>Z</given-names></string-name>, <string-name name-style="western"><surname>Nater</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Ou</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Yang</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Morrison</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Coleman</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Malik</surname><given-names>F</given-names></string-name>, et al</person-group>. <article-title>Modulation of macropinocytosis-mediated internalization decreases ocular toxicity of antibody&#8211;drug conjugates</article-title>. <source>Cancer Res</source>. <year>2018</year>; <volume>78</volume>(<issue>8</issue>):<fpage>2115</fpage>&#8211;<lpage>2126</lpage>. doi: <pub-id pub-id-type="doi">10.1158/0008-5472.CAN-17-3202</pub-id>.<pub-id pub-id-type="pmid">29382707</pub-id></mixed-citation></ref><ref id="cit0046"><label>46.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Lewis</surname><given-names>ID</given-names></string-name>, <string-name name-style="western"><surname>Rawling</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Dyson</surname><given-names>PG</given-names></string-name>, <string-name name-style="western"><surname>Haylock</surname><given-names>DN</given-names></string-name>, <string-name name-style="western"><surname>Juttner</surname><given-names>CA</given-names></string-name>, <string-name name-style="western"><surname>To</surname><given-names>LB</given-names></string-name></person-group>. <article-title>Standardization of the CFU-GM assay using hematopoietic growth factors</article-title>. <source>J Hematother</source>. <year>1996</year>; <volume>5</volume>(<issue>6</issue>):<fpage>625</fpage>&#8211;<lpage>630</lpage>. doi: <pub-id pub-id-type="doi">10.1089/scd.1.1996.5.625</pub-id>.<pub-id pub-id-type="pmid">9117251</pub-id></mixed-citation></ref><ref id="cit0047"><label>47.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Hinton</surname><given-names>PR</given-names></string-name>, <string-name name-style="western"><surname>Johlfs</surname><given-names>MG</given-names></string-name>, <string-name name-style="western"><surname>Xiong</surname><given-names>JM</given-names></string-name>, <string-name name-style="western"><surname>Hanestad</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Ong</surname><given-names>KC</given-names></string-name>, <string-name name-style="western"><surname>Bullock</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Keller</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Tang</surname><given-names>MT</given-names></string-name>, <string-name name-style="western"><surname>Tso</surname><given-names>JY</given-names></string-name>, <string-name name-style="western"><surname>V&#225;squez</surname><given-names>M</given-names></string-name>, et al</person-group>. <article-title>Engineered human IgG antibodies with longer serum half-lives in primates</article-title>. <source>J Biol Chem</source>. <year>2004</year>; <volume>279</volume>(<issue>8</issue>):<fpage>6213</fpage>&#8211;<lpage>6216</lpage>. doi: <pub-id pub-id-type="doi">10.1074/jbc.C300470200</pub-id>.<pub-id pub-id-type="pmid">14699147</pub-id></mixed-citation></ref><ref id="cit0048"><label>48.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Hu</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Smyth</surname><given-names>GK</given-names></string-name></person-group>. <article-title>Elda: extreme limiting dilution analysis for comparing depleted and enriched populations in stem cell and other assays</article-title>. <source>J Immunol Methods</source>. <year>2009</year>; <volume>347</volume>(<issue>1&#8211;2</issue>):<fpage>70</fpage>&#8211;<lpage>78</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.jim.2009.06.008</pub-id>.<pub-id pub-id-type="pmid">19567251</pub-id></mixed-citation></ref><ref id="cit0049"><label>49.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>H&#228;nel</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Sch&#246;nle</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Neumann</surname><given-names>AS</given-names></string-name>, <string-name name-style="western"><surname>Nixdorf</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Philipp</surname><given-names>N</given-names></string-name>, <string-name name-style="western"><surname>Sponheimer</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Leutbecher</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Emhardt</surname><given-names>A-J</given-names></string-name>, <string-name name-style="western"><surname>Magno</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>B&#252;cklein</surname><given-names>V</given-names></string-name>, et al</person-group>. <article-title>Combining venetoclax and azacytidine with T-cell bispecific antibodies for treatment of acute myeloid leukemia: a preclinical assessment</article-title>. <source>Leukemia</source>. <year>2024</year>; <volume>38</volume>(<issue>2</issue>):<fpage>398</fpage>&#8211;<lpage>402</lpage>. doi: <pub-id pub-id-type="doi">10.1038/s41375-023-02127-0</pub-id>.<pub-id pub-id-type="pmid">38212534</pub-id><pub-id pub-id-type="pmcid">PMC10844082</pub-id></mixed-citation></ref><ref id="cit0050"><label>50.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Zhu</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Liu</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Wang</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Zhu</surname><given-names>H</given-names></string-name></person-group>. <article-title>Treatment&#8208;related adverse events of antibody&#8211;drug conjugates in clinical trials: a systematic review and meta&#8208;analysis</article-title>. <source>Cancer</source>. <year>2023</year>; <volume>129</volume>(<issue>2</issue>):<fpage>283</fpage>&#8211;<lpage>295</lpage>. doi: <pub-id pub-id-type="doi">10.1002/cncr.34507</pub-id>.<pub-id pub-id-type="pmid">36408673</pub-id><pub-id pub-id-type="pmcid">PMC10099922</pub-id></mixed-citation></ref></ref-list></back></article>
        
    </metadata>
</record>
    </GetRecord>

</OAI-PMH>